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Abstract
The Retinoblastoma protein (pRB) is a key regulator of cell proliferation in the G1
phase of the cell cycle. The LxCxE binding cleft is a highly conserved region of pRB. Using
a knock-in mouse model, called Rb1∆L, with disrupted pRB and LxCxE interactions, our lab
has shown that epithelial cells from Rb1∆L/∆L mice do not respond to TGF-β1 mediated
growth arrest. Using shRNAs to deplete the expression of components of LxCxE motif
containing complexes, data showed that SAP18 is not involved in TGF-β1 mediated growth
arrest. However, depletion of SAP30 and MTA2 compromised TGF-β1 mediated growth
arrest. Furthermore, depletion of MTA2 resulted in derepression of E2F target genes in
response to TGF-β while depletion of SAP30 repressed the expression of E2F target genes.
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1

Introduction
1.1 Retinoblastoma; the first tumor suppressor to be
identified

1.1.1

Retinoblastoma and RB1 Discovery
Before the “two hit” hypothesis proposed by Knudson, it was believed that a large

number of mutations are required for tumorigenesis. Using the retinoblastoma cancer
model, Knudson proposed that this disease could arise from as few as two mutations. He
proposed that in familial form of retinoblastoma, in which a germline mutation is present,
a second somatic mutation is required for tumorigenesis whereas in sporadic
retinoblastoma, both somatic mutations are required for tumorigenesis (1). This notion
was supported by the fact that sporadic cases have a later onset (1). A decade later,
several studies cloned a locus containing the product of retinoblastoma susceptibility
gene (pRB) and mapped the gene on chromosome 13 (2-5). Studies conducted after
cloning of the RB1 gene showed that pRB is a nuclear phospho-protein with the ability to
bind to DNA (6-8). In addition, the germline mutation in a single allele of RB1 promoted
a loss of heterozygosity, a chromosomal event that results in loss of the entire gene,
confirming Knudson’s two hit hypothesis (9).
With the emergence of transgenic mouse models, three independent studies
reported that heterozygous mice for RB1 did not develop retinoblastoma (10-12). More
importantly, these animals survived and did not show any overt phenotype except low-
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penetrance pituitary tumour formation reported by Jacks and colleagues (10). The RB1
null mice died in the early embryonic stages due to apoptosis in the nervous system (1012). These findings led to the discovery of other members of pocket protein family and
the suggestion that pRb function can be compensated by other pocket protein family
(p107 and p130) in mice. Development of the first animal model with Rb1/p107 null cells
revealed evidence for the compensation of the pocket proteins family as these mice
developed retinoblastoma (13). Since the discovery of RB1, many studies have examined
different roles for pRB in cancer progression and have expanded our knowledge of
different pRB functions.

1.1.2

Structure of pRB
pRB contains 928 amino acids, and consists of three domains, the N- terminal

domain, the C-terminal domain and a “small pocket” linker domain. This pocket domain
contains two major domains, A and B, which are linked by a spacer region. Many
proteins such as LxCxE (Leu-X-Cys-X-Glu; X= any amino acid) partners, E2 promoter
binding factor (E2F) and cyclin dependent kinase (CDK) complexes bind to the small
pocket domain (14). The small pocket together with the C-terminal domain creates the
“large pocket” which is required and sufficient for the ability of pRB to induce cell cycle
arrest (15, 16).
The LxCxE binding cleft in the small pocket region is one of the most highly
conserved regions of pRB (17). This cleft was initially identified as a contact site for
LxCxE motifs in viral oncoproteins such as simian virus 40 (SV40) large T antigen,
adenovirus E1A and human papillomavirus E7 (HPV E7) (18, 19). This cleft interacts
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with over 30 cellular proteins. Many of these proteins have the ability to modify
chromatin, including Histone deacetylase 1/2 (HDAC1/2), DNA methyltransferases 1
(DNMT1), Brahma Related Gene 1 (BRG1) (20) (Figure 1-3). The majority of research
in the pRB field has focused on the role of E2F transcription factors in pRB`s tumor
suppressor function with little focus on how proteins with LxCxE motif contribute to this
function. This thesis focuses on an aspect of how these proteins with LxCxE motif
contribute to pRB`s ability to act as a tumor suppressor.
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Figure 1-1 Domain structure of pRB
The domain structure of pRB is shown with the large pocket, small pocket and Cterminal regions. pRB binds to over one hundred protein partners and mediates
transcriptional regulation of hundreds of target genes.
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1.1.3

E2F transcription factors

1.1.3.1

Structural features of E2Fs

The protein-protein interactions between pRb and E2F transcription factors are
well characterized. E2Fs are a family of transcription factors with many common
features. They are divided into two categories based on their transcriptional activity:
activator E2Fs and repressor E2Fs. Activator E2Fs consist of E2F1, E2F2 and E2F3a
while E2F3b, E2F4, E2F5, E2F6, E2F7 and E2F8 are classified as repressor E2Fs (21).
All E2Fs except E2F7 and E2F8 interact with dimerization partner (DP) proteins
through the dimerization domain. DP proteins are required to enhance DNA binding
activity of E2Fs (22-24). There are three different DP proteins (DP1, DP2/3, DP4) but not
much is known about their activity (25). E2F subunits determine the specificity of
E2F/DP complex rather than DP subunits (25). E2F-DP interactions are necessary for
E2Fs function, as E2F1-6 are not capable of interacting with deoxyribonucleic acid
(DNA) without dimerization. E2F7 and E2F8 contain two DNA binding domains
allowing them to interact with DNA independently of DP proteins (26, 27). E2F1, E2F2
and E2F3a are structurally similar and share many domains such as the transactivation
domain. This domain is responsible for E2F target genes` activation by recruiting the
transcription machinery such as transcription factor II D (TFIID), p300 and
triiodothyronine receptor auxiliary protein (TRAP) to E2F target genes promoters (2830). Pocket proteins also interact with this domain to block its ability to drive
transcription of E2F target genes (31, 32). E2F 6-8 do not contain a transactivation
domain and act as a constitutive repressor independently of pocket proteins (21).
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1.1.3.2

E2F binding sites of pRB

pRB contains two distinct binding sites to interact with E2F1: The large pocket
and the C-terminal region of pRB (33). The large pocket region, also called the “general
site” of pRB, interacts with the transactivation domain of E2F1-4. The C-terminal region
of pRB, also known as the “specific site”, uniquely binds to the marked box domain of
E2F1 (34). The ‘general site’ functions in proliferative control while the ‘specific site’
functions in E2F1 induced apoptosis (33-35). However, the exact mechanism by which
specific site regulates E2F1 induced apoptosis remains to be investigated. Moreover,
E2F1-pRB complex through specific site showed low affinity for the canonical E2F
recognition sequence (33) and was resistant to disruption by E1A infection and CDK
phosphorylation (36). These data suggest that this complex is regulated through distinct
mechanisms and functions in nontraditional pathways compared to other E2F-pRB
complexes.

1.1.3.3

Roles of E2F transcription factors

Multiple gene targeted mouse models have been developed to investigate the role
of each individual E2F. The data showed that all the single knockout mice are viable
suggesting that none of the E2Fs is required in development. However, there are some
defects in different tissue for each knockout suggesting that E2Fs may have tissue
specific roles (21). For instance, E2F4-/- mice show maturation defects in hematopoietic
lineages and E2F2-/- mice show a higher activity of T-Cell receptor signaling leading to
development of autoimmune diseases (37, 38).
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Although activator E2Fs appear to have redundant roles in proliferative control,
E2F1 shows a unique connection to apoptosis. This unique function was discovered by
the fact that E2F1 null mice showed a defective apoptosis in their lymphocytes (45).
More importantly, none of the other E2F knockout mice showed any defect in apoptosis
suggesting that this is a unique function of E2F1(38-44). During DNA damage, E2F1
effectively activates an apoptotic program through the activation of p53 or its homologue
p73 (46-48). It has been shown that E2F1 activates a series of apoptotic targets such as
the p19-alternate open reading frame (ARF), which is responsible for inhibiting the
degradation of p53 (49). E2F1 also acts to induce apoptosis through the direct activation
of p73 (50).

1.1.4

Mechanisms of pRB-mediated gene repression
Briefly, pRB binds to E2Fs and inhibits their transcriptional activity to induce G1

arrest. In the G1 phase of the cell cycle, pRB is phosphorylated and bound to E2Fs and
co-repressors, which results in transcriptional repression of S phase entry genes. During
late G1, the phosphorylation of pRB by CDK4/6/Cyclin D complexes alleviates
repression of E2F. Further phosphorylation of pRB by CDK2/Cyclin E drives the cell
into S-phase (64) (Figure 1-4).
In addition to pRB and E2Fs interactions, which masks the transactivation domain
of E2F and inhibits E2F transcriptional activation, pRB and other members of the pocket
protein family recruit multiple co-factors that change the activation state of target genes
(52). The best-characterized interactions occur between pRB and HDACs. HDACs are
responsible for removing acetyl groups from activated histones to induce transcriptional
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repression (53). The pRB-HDAC complex strengthens pRB-E2F mediated repression
during the G1 phase of the cell cycle (54, 55, 51 and 56). pRB also interacts with other
proteins to regulate transcription and affect chromatin dynamics. One such example is
DNMT1, which interacts with pRB to promote DNA methylation and repress
transcription (57). RBP2 is another pRB binding protein involved in chromatin
regulation. This protein is a demethylase, which removes methyl groups of an active
transcription mark, named trimethylated H3K4 (58-61). Further experiments showed that
Rbp2 knockdown in Rb1 null MEFs opposes proliferation of these cells while promoting
differentiation (62).
As mentioned here, some LxCxE binding proteins can change the activation state
of target genes. However, the exact mechanisms by which these proteins change the
transcriptional program remains to be discovered.
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Figure 1-2 The proposed model of pRB function
In the G1 phase of the cell cycle, hypophosphorylated pRB acts as a tumor suppressor by
binding to E2Fs and inhibiting transcriptional activation of genes required for S phase
entry. When cells progress to the S phase, CDK-cyclins complexes phosphorylate pRB
and inhibit its activity. The phosphorylation of pRB releases E2F-DP, allowing them to
activate the transcription of genes, which are required for S phase entry.
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1.1.5

Biological functions of pRB

1.1.5.1

Regulation of cell cycle

In the G1 phase of the cell cycle, hypophosphorylated pRB masks the
transactivation domain of E2Fs bound to their DP protein partners, which blocks the
activation of E2F target genes such as CCNE1, CCNA2 and E2F1 (63). pRB-E2F-DP
complexes are also able to recruit chromatin regulatory factors (CRFs) to further repress
the transcription of these genes (64). As cells progress into the S phase, CDK/Cyclin
complexes phosphorylate pRB, leading to release of E2F/DP complexes. Free E2Fs drive
the transcription of E2F target genes required for the S phase entry.

1.1.5.2

pRB and controlling cell death

It is believed that pRB has a dual role in apoptosis through multiple mechanisms
(65, 66). The first evidence for the anti-apoptotic role of pRb rose from an experiment
where Rb null mice showed an increased level of apoptosis (10). However, recent studies
revealed that this phenotype is due to the deregulation of cell cycle regulators and
overproliferation of the placenta which result in hypoxia in embryonic tissues and is not
cause by E2Fs (67-69). In contrast, recent studies have shown that pRB has an apoptotic
role in highly proliferative cells (65, 70 and 71). In these studies, the
hyperphosphorylated pRB forms a complex with E2F1 and histone acetyltransferase
p300/CBP-associated factor (P/CAF) at the promoter of proapoptotic genes such as
caspase7 and p73 driving their expression to induce apoptosis (65). Moreover, a recent
study revealed another mechanism for apoptotic activity of pRB. This study showed that
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pRB expression increases tumor necrosis factor-α (TNF-α)-induced apoptosis, which
depends on its localization to the mitochondrial outer membrane and acts in a Baxdependent manner (72).

1.1.5.3

pRB and the maintenance of genome stability

pRB is also able to both prevent and respond to genotoxic stress. A recent study
showed that disruption of pRB function by oncogenes could cause replicative stress
during the S phase of the cell cycle (73). This study showed that pRB inactivation by
oncoproteins results in an uncoordinated S phase entry. This leads to increased
replication stress which ultimately causes DNA damage and genome instability (73).
Many of E2F target genes involved in chromatin condensation, spindle
checkpoint and chromosome segregation have been identified (74, 75). Mitotic arrest
deficient 2 (Mad2) protein, which is responsible for proper chromosome segregation, is
an example of direct E2F target gene. pRB inactivation deregulates the expression of
Mad2, which leads to mitotic defects and aneuploidy (76). These data suggest that pRB
has essential roles in maintaining genome stability beyond its G1/S function.
pRB is also essential for maintaining chromosome stability and preventing tumor
growth in mice. Using an LxCxE mutant mouse model, our lab showed that the LxCxE
motif of pRB recruits the chromosome associated protein D3 (CAP-D3) protein to the
centromeric heterochromatin. We also showed that recruitment of CAP-D3 to this region
is required for condensin II complex formation and maintaining chromosome stability
(77). Furthermore, these results were supported by findings from other research groups
using fruit flies and human retinal cells (78, 79).

12

1.1.5.4

The role of pRB in senescence

pRB plays an essential role in senescence through the stable repression of E2F
target genes and heterochromatin formation (80, 81). Studies over several years have
revealed how pRB contributes to senescence. It has been shown that the activator E2Fs
are recruited to promyelocytic leukemia (PML) nuclear bodies by the tumor suppressor
PML. This leads to transcriptional repression of E2F target genes, which causes stable
cell cycle arrest in a pRB-dependent manner (82). These findings provide an explanation
for how pRB mediates the stable repression of E2F target genes in oncogene-induced
senescence, but how pRB interacts with other co-factors to perform its role in inducing
stable cell cycle exit remains to be addressed.
Recently, a study showed that large tumor suppressor kinase 2 (LATS2 kinase)
mediates the formation of p130/DP, pRB, E2F and MuvB (DREAM) complexes at E2F
target gene promoters. The formation of this complex represses transcription of E2F
target genes and induces senescence (83). In addition, LATS2 kinase phosphorylates dual
specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and in turn
phosphorylates LIN52, which is required for DREAM assembly (84). It is interesting to
mention that p130 and p107 alone are not sufficient for the oncogenic Ras induced
senescence (85). However, p130 and p107, but not pRB, were found in the DREAM
complex (86). These findings provide a mechanism for oncogene induced senescence.
pRB could be responsible in recruiting p107 and p130 to the DREAM complex in
oncogene induced senescence; however, how pRB contributes to this mechanism needs to
be investigated.
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1.1.6

pRB in breast cancer

pRB is the central regulator of the cell cycle that is inactivated in the majority of
human cancers. Primary tumors analyses have shown that 20-35% of tumors lose pRB
expression and 7-37% of tumors show loss of heterozygosity or other alterations of the
RB1 locus (87-90).
In breast cancer, pRB function is abrogated via multiple mechanisms such as loss
of p16ink4a, which promotes cell growth (91, 92). Microarray analyses have revealed
that pRB/E2F complex regulates approximately 150 target genes involved in cell cycle
control (93). Furthermore, it has been shown that RB1 deficiency results in deregulation
of several E2F target gene such as proliferating cell nuclear antigen gene (PCNA),
CCNE1 (Cyclin E1 gene) and CCNA2 (Cyclin A2 gene), all of which are required for cell
cycle progression (94). It is logical that elevated expression levels of these target genes
are responsible for the accelerated proliferation rates observed in RB1-deficient breast
cancer cells and tumors.
In addition, the influence of RB1 status on disease severity has been investigated
in a broad range of tumors. In the context of breast cancer, these analyses have revealed
that RB1 loss correlates with advanced disease and often estrogen receptor (ER)-negative
disease (95, 96). Although there are many data showing E2F-pRB mediated gene
expression changes in breast cancer cells and tumors, the main question of whether direct
RB1 loss or various upstream effects on the pRB pathway are responsible for these
changes in gene expression remains to be addressed. Answering this question could lead
to improved treatment for breast cancer patients.
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1.1.7

Importance of LxCxE interactions in pRB function
The majority of research in the pRB field has focused on its role in binding and

inhibiting E2F transcription factors, with little focus on the role of LxCxE-pRB
interactions in pRB`s tumor suppressor function. The LxCxE binding motif interacts with
many factors (20). Initial in vitro studies have showed that the mutation of the LxCxE
binding cleft prevents pRB induced growth arrest in fibroblasts. However, the LxCxE
mutant was sufficient to maintain growth arrest in terminally differentiated muscle tissue
(97). Later study by La Thangue group called into question the effect of LxCxE
interactions in growth arrest, as LxCxE mutants were dispensable for growth arrest (98).
Thus, the development of mouse models that disrupt the interaction between pRB and
LxCxE binding cleft were necessary to study the function of this domain in multiple
cellular contexts in vivo.
In order to understand the importance of the LxCxE binding cleft in pRb, our lab
created a gene-targeted mouse model. This mouse, called Rb1ΔL, carries three
substitutions which disrupt the interaction between pRb and LxCxE containing proteins,
whereas interactions with other molecules, such as E2F transcription factors, are intact
(99) (Figure 1-5). In accordance with La Thangue group study, MEFs isolated from
Rb1ΔL/ΔL mice have the ability to maintain proliferative control in asynchronous growing
cultures, in response to serum starvation and confluence arrest (99). Furthermore, these
mice are viable, fertile and do not develop spontaneous tumor.
In the context of tumor initiation, Rb1ΔL/ΔL showed several mitotic defects leading
to chromosomal instability, which resulted in tumour formation in conjunction with the
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p53 null model (77, 99). It has been demonstrated that CAP-D3, the condensin II
complex subunit, which is essential for proper chromosome segregation during mitosis,
interacts with pRB through the LxCxE binding cleft (78). This provides a mechanistic
explanation for genomic instability seen in the study by our lab (85).
Finally, in the context of cellular senescence, pRB recruits different co-factors
from normal physiological G1 arrest (208, 213). Using the Rb1ΔL/ΔL mouse model, our
lab showed that LxCxE mutants prevent Ras-induced senescence (100). Although no
specific LxCxE partners have been identified, Jarid1a (Rbbp2) was shown to regulate
senescence by interaction with pRB. Even though it has not been determined whether
Jarid1a interacts with pRB through the LxCxE binding cleft, this presents a possible
mechanism of regulation (101).
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A

B

Figure 1-3 The knock-in mouse strain with disrupted LxCxE interactions
A) pRB interaction with the human papillomavirus (HPV) E7 through the LxCxE binding
cleft. Amino acids mediating the interaction are shown in turquoise. The Rb1∆L mutation
changes these residues to alanines (red) which results in disrupting the pRB-LxCxE
interaction
B) ∆LxCxE mice are viable and develop relatively normally. (Adopted from Francis, S.,
MCB 29: 4455-66)
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1.1.8

LxCxE binding partners
As mentioned above, the LxCxE binding motif interacts with many factors (20).

This introduction focuses on the complexes relevant to this thesis (Table 1-1).

1.1.8.1

Sin3 complex

Sin3 is a nuclear protein, which consists of Sin3A and Sin3B isoforms in human
(102). In addition to these isoforms, splice variants occur in these genes, adding more
complexity to these isoforms (103). Structural analyses of Sin3 have revealed that there
are four conserved regions within this protein called paired amphipathic helix (PAH)
domains which are responsible for protein-protein interactions (104). Another conserved
region in Sin3 is the HDAC interacting domain (HID) located between PAH3 and PAH4
domains. Both HID and PAH domains are essential for transcriptional repression activity
of Sin3 (105, 106).
The Sin3 complex consists of several components including retinoblastoma
associated protein 46 (RbAp46), RbAp48, HDAC1, HDAC2, Sin3 Associated
Polypeptide-30 kDa (SAP30) and Sin3 associated polypeptide-18 kDa (SAP18) (107).
RbAp46 and RbAp48 are highly similar in their sequence (90% homology) (108-110).
Furthermore, they have been identified using immobilized pRB (108, 109). Interestingly,
these proteins are capable of interacting with histone H4 and H2A suggesting that they
may be involved in Sin3 complex interaction with histones (111).
SAP30 is one of the unique components of Sin3 complex. SAP30 is a highly
conserved protein from yeast to human. There are several biochemical evidences
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suggesting that this protein is a component of the Sin3/HDAC complex in yeast and
mammalian cells (112). In mutational analysis of yeast, disruption of the SAP30 shows
the similar phenotypes as the strains with Sin3 disruption, suggesting that SAP30 plays
an essential role in the Sin3 complex (112). SAP30 directly binds to multiple subunits of
the Sin complex, including RBBP4/7 and HDAC1, suggesting that SAP30 may play a
role in stabilizing the complex (112). In addition to serving a role a stabilizing molecule
in Sin3 complex, several studies indicate that SAP30 may serve as a bridging protein
between the Sin3 complex and other transcription factors and corepressors such as
Papillomavirus binding factor (PBF) and Yin Yang 1 (YY1). PBF acts as a repressor of
HPV transcription through the recruitment of the Sin3/HDAC complex to the promoters
of certain HPV proteins via direct interaction with SAP30 (113). SAP30 also interacts
with YY1 and enhances YY1 induced repression through direct recruitment of HDAC1
(114, 115).
SAP18 is another core protein in the Sin3 complex, which directly interacts with
HDAC1 (116). SAP18 has been identified to be a part of other complexes such as
apoptosis-and splicing-associated protein (ASAP).This complex also contains an RNAbinding protein (RNPS1) and a caspase (Acinus) (117). In Drosophila melanogaster,
SAP18 plays an important role in mRNA splicing, by interacting with the homolog of
Pinin (dPnn) (117). More recently, another component of the Sin3 complex has been
identified in yeast and mouse, called the suppressor of defective silencing 3 (SDS3) (118120). SDS3 is an integral component of the Sin3 complex, which interacts with HID
domain of Sin3 and regulates the catalytic activity of the Sin3 complex (121, 122).
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Furthermore, depletion of SDS3 compromises deacetylation of pericentric
heterochromatin, leading to aneuploidy and defective karyokinesis (123).

1.1.8.2

Mi-2/NuRD (nucleosome remodeling and deacetylation)
complex

Mi-2/NuRD and Sin3 complexes share several components including RbAp46,
RbAp48, HDAC1 and HDAC2. In addition, Mi-2/NuRD complex contains other subunits
such as Mi-2α, Mi-2β, p66α, p66β and metastasis associated 1 family member 2 (MTA2)
(124-126). Mi-2 proteins contain chromodomain and switching defective/sucrose nonfermenting (SWI2/SNF2)-type helicase/ATPase domains with chromatin remodeling
activity (127, 128). p66α and p66β directly interact with the methyl CpG binding
proteins, MBD2b and MBD3. However, their exact role in humans remains to be
investigated (129).
The MTA protein family consists of three proteins including MTA1, MTA2 and
MTA3 (130). MTA proteins localize to the nucleus except MTA1, which localizes to
both the cytoplasm and nucleus (130-132). This family contains several common
domains including the SANT (SWI, ADA2, N-CoR and TFIIIB-B) domain which is
involved in DNA binding, bromo-adjacent homology (BAH) domain which is essential
for protein-protein interactions and the egl-27 and MTA1 homology (ELM) domain (131,
132). These common domains suggest that MTA proteins may function in signal
transduction and transcriptional regulation.
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MTA2 is a component of the NuRD complex, which represses transcription and
exerts HDAC activity (124). MTA2 is the first member of MTA family to be found in the
NuRD complex. This protein contains putative zinc fingers and leucine zipper domains
(133). MTA2 has been identified in association with HDAC and p53, which results in
deacetylation of p53 and repression of p53 dependent transcription (134).

1.1.8.3

C-terminal binding protein (CtBP) complex

It has been shown that pRB recruits histone deacetylase to mediate transcriptional
repression of E2F target genes. However, many genes subjected to E2F-pRB mediated
repression are not activated following “trichostatin A” treatment, a histone deacetylase
inhibitor, suggesting additional factor may contribute to the repression.
CtBP isoforms one, two and three are cellular proteins that bind to the C-terminal
region of the human adenovirus E1A proteins (135-137). CtBP proteins are highly
conserved among invertebrates and vertebrates (137). CtBP proteins play an important
role in development and oncogenesis (137). CtBP protein is recruited by a protein with
PLDLS motif to the promoter of genes such as Knirps and Snail to repress transcription
of these genes in fruit flies (136, 138). In addition, it has been shown that mammalian
CtBP protein is recruited to E2F target genes promoters through an interaction with the
C-terminal interacting protein (CtIP) (135). Since CtIP does not directly bind to DNA, it
appeared that CtIP bridges CtBP to target promoters by interaction with pRB or p130 and
then E2F. However, the exact mechanism by which CtBP represses transcription of E2F
targets needs to be investigated.
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Table 1-1 pRB-LxCxE chromatin regulating complexes

Complex

Subunits

Sin3

SAP18

RBP1

Sin3

NuRD

LSD1

MTA2

Mi-2a/b

CtBP

LSD1

CtIP

CDYL

HDAC

RBBP

1/2

4/7

HDAC

RBBP

1/2

4/7

HDAC
1/2

CtBP

SDS3

ING1/2

SAP30

p66a/b

MBD3b

MBD3a

GLP

CoREST

LCoR
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1.2 TGF-β, a highly pleiotropic cytokine: An overview
Transforming growth factor-β (TGF-β) isoforms one, two and three are members
of a large family of cytokines with similar structure. TGF-β regulates different biological
functions such as apoptosis, cell growth, T-cell activation and differentiation (139). TGFβ isoforms act as tumor suppressors whose growth suppressive function is overcome
during cellular transformation (140, 141). In contrast, TGF-β also regulates processes
such as cell motility, which can stimulate metastatic dissemination of cancer cells (142).
From this perspective, understanding the mechanism of action of TGF-β signaling holds
great promise for developing new cancer therapies.

1.2.1

Overview of signal transduction by TGF-β
TGF-β initiates signaling cascade by inducing two serine/threonine kinase

receptors. Upon ligand binding, the TGF-β type II receptor (TβIIR) forms a complex with
the TGF-β type I receptor (TβIR) and phosphorylates TβIR at its glycine-serine-rich
domain (GS domain). Activated TβIR in turn phosphorylates and activates receptorregulated Smad (R-Smad) proteins (143-145). Phosphorylated R-Smads then bind to
Smad4 through their mad homology 2 (MH2) domains, and translocate into the nucleus
(146-149). Once in the nucleus, these complexes mediate the expression of different
genes such as plasminogen-activator inhibitor-1 (PAI-1), p15, p21 and collagen by
interacting with various transcription factors and co-factors (150-154). (Figure 1-1)
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Figure 1-4 The current model of TGF-βsignalinginthecellcycle
In the presence of TGF-β ligand, TβIR is phosphorylated which allows it to
phosphorylate and activate R-Smads. Activated R-Smad then binds to co-Smad and
translocates into the nucleus. Once in the nucleus, Smad4 recruits other cofactors, which
results in regulation of many genes and dephosphorylation and activation of pRB in the
G1 phase of the cell cycle.
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Components of TGF-β signaling pathways

1.2.2
1.2.2.1

TGF-β ligands and receptors

The TGF-β superfamily includes over 30 polypeptides. They are divided into two
subfamilies: the TGF-β subfamily which includes TGF-βs (1-3), activins (A, B), nodal
and myostatins, and the bone morphogenetic protein (BMP) subfamily which includes
BMPs (1-9), Anti-Müllerian hormone (AMH) and growth and differentiation factors
(GDFs) (155, 156). These ligands are synthesized as the C-terminal domain of a
precursor molecule. The signal peptide region is cleaved before secretion and these
cleaved cytokines remain inactive due to the function of the latency-associated peptide
(LAP) (157-159). Once in the extracellular matrix (ECM), TGF-β is activated by
proteases that remove LAP, resulting in the stable and active dimeric form of the TGF-β
cytokine (146).
TGF-β triggers signaling events by inducing heterodimerization of TβIR and
TβIIR. Both receptors contain a single transmembrane domain, an N-terminal domain
and a C-terminal domain (160). A complex of TβIR and TβIIR homodimers is formed
after ligand binding creating a tetrameric structure. Once assembled, the constitutively
active TβIIR phosphorylates TβIR at its cytoplasmic GS domain. Phosphorylation of the
serine residues within the GS domain creates a docking site for R-Smads (161, 162).
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1.2.2.2

Smad proteins

1.2.2.2.1

Structure and diversity

Smad proteins were originally identified in Drosophila melanogaster and
Caenorhabditis elegans (163, 164). There are eight Smad proteins in mammals that are
divide into three subtypes: R-Smads including Smad2 and Smad3 for TGF-β signalling
pathways, Smad1, Smad5 and Smad8 for BMP signaling pathways, common-partner
Smads (Co-Smads) such as Smad4 and inhibitory Smads (I-Smads) such as Smad6 and
Smad7 (165-167).
R-Smad and Smad4 proteins contain two conserved domains: The MH1 domain
in the N-terminal region and the MH2 domain in the C-terminal region bridged by a
linker region (168, 146). The MH2 domain in R-Smads contains a ‘SSXS’ motif
phosphorylated by TβIR for Smad activation (143, 170 and 171). Smad4 does not contain
the ‘SSXS’ sequence in its MH2 domain, Therefore, TβIR is not able to phosphorylate
Smad4 (169, 172). The linker region contains a ‘PPXY’ motif, a regulatory site for Smad
activation, which promotes Smad degradation via proteasomal machinery (146). I-Smads
(Smad6 and Smad7) lack the MH1 domain and the ‘SSXS’ motif (173) (Figure 1-2).
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Figure 1-5 Diagrammatic representation of Smads
The MH1 domain is shown in blue and the MH2 domain is shown in green.
Phosphorylated serine residues in the SSXS motif of R-Smads are shown with asterisks.
NLS: nuclear localization signal, NES: nuclear export signal, PY: PPXY motif (Adopted
from Moustakas, A. et al. J Cell Sci (2001) 114: 4359-4369)
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1.2.2.2.2

Mechanism of transcriptional regulation by Smads

In resting cells, R-Smads are located in the cytoplasm and they interact with
different proteins such as the Smad anchor for receptor activation (SARA). SARA binds
to R-Smads to inhibit receptor interaction. This protein also prevents nuclear entry of
unphosphorlated Smads by interacting with R-Smads (174, 175). Upon TGF-β
stimulation, activated receptor complexes phosphorylate R-Smads at their ‘SSXS’ motif.
In this stage, SARA mediates and facilitates the interactions between R-Smads and TGFβ receptors. Once R-Smads are phosphorylated, they bind to Smad4 for nuclear entry and
complex formation. There are several studies showing that Smad4 is essential for
mediating of TGF-β signaling (149, 172, 176 and 177). For instance, TGF-β
responsiveness is rescued by ectopic expression of Smad4 in a Smad4 null cell line,
suggesting that Smad4 is required for TGF-β signaling (178).
Once the complex is formed, R-Smads bind to the major groove of DNA.
However, Smad2 and Smad4 do not bind to DNA (168, 179). A specific DNA sequence
(5’- CAGAC-3’) termed as the Smad-binding element (SBE), is an essential factor in
recognition of DNA by Smad complexes (150, 180 and 181). Many Smad target genes
have SBEs in their promoters (182-184). Since Smads interact with SBEs with low
affinity, DNA binding partners are required to make specific high affinity interactions of
Smads and SBEs and drive transcriptional responses of Smads. Examples of these DNA
binding partners are forkhead box H1 (FoxH1) family (e.g., Fast1), Rel/ nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) family (e.g., NF-κB2),
runt-related transcription factor (Runx), E-box, p300, HDAC, Sloan-Kettering Institute
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oncogene (Ski), SKI-like oncogene (SnoN) and E2Fs which regulate gene expression
(185-193).

Regulation of TGF-β signaling

1.2.3

As a critical and important signaling pathway, the TGF-β superfamily signaling is
tightly regulated to ensure a proper physiological response. Thus, there are several
regulatory mechanisms for this pathway at multiple levels.

1.2.3.1

Regulation of ligand

TGF-β remains in an inactive form after secretion by binding to the LAP. TGF-β
must cut off LAP to obtain its function (194). Many extracellular proteases such as
thrombospondin-1, cathepsin D and matrix metalloproteinase 2 (MMP2) are responsible
for this cleavage (195-197).

1.2.3.2

Regulation of receptor activation

There are many mechanisms involved in regulation of receptor activation. For
instance, FK506-binding protein 12 (FKBP12) is able to terminate signal transmission by
blocking the phosphorylation site of TβIR (198, 199). The internalization of receptors is
another mechanism to regulate TGF-β signaling at the receptor level. This process occurs
through two pathways: clathrin-mediated endocytosis of the receptors and lipid raft or
caveolin-mediated endocytosis. In clathrin-coated endocytosis, vesicles bring the
receptors to the cell surface in the absence of TGF-β. These vesicles also bring the
activated receptor in close proximity to their R-Smad to facilitate their phosphorylation
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(200-202). However, lipid rafts negatively regulate the receptors (200, 203). Upon ligand
stimulation, the Smad7-WW-HECT domain E3 ligases complex interacts with the TGF-β
receptors. This interaction induces lipid raft dependent endocytosis, causing receptor
degradation by proteasomal machinery.

1.2.3.3

Regulation of Smad activity and levels

Smad activity and levels are tightly regulated by a variety of different
mechanisms and complexes. For instance, phosphorylated R-Smads compete with the
ErbB2/Her2-interacting protein (Erbin) to bind to Smad4 (204). Additionally, protein
phosphatase, Mg2+/Mn2+ dependent, 1A (PPM1A) removes the phosphate group from
nuclear R-Smads to inactivate and bring them back to the cytoplasm (205). Furthermore,
I-Smads, Smad6 and Smad7, regulate TGF-β signaling. Smad6 is an inhibitory protein
for the BMP signaling pathway whereas Smad7 functions in both the BMP and TGF-β
signaling pathways (206, 207). Smad6 and Smad7 recruit E3 ligases for degradation of
BMP and TGF-β receptors, respectively (208, 209). In addition, Smad6 and Smad7
interfere with R-Smads for binding to the TβIR, inhibiting the phosphorylation of RSmads (206, 210). Interestingly, TGF-β activates the expression of Smad6 and Smad7
providing a negative feedback loop (211, 206).

1.2.4

Smad-independent signaling
In addition to Smad-dependent signaling, there are several Smad-independent

TGF-β signaling pathways through the crosstalk with other pathways. One example of
these pathways is mitogen activated protein kinase (MAPK) family signaling pathways
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(212). C-Jun N-terminal Kinase (JNK), extracellular substrate-regulated kinase (Erk) and
p38 MAPK kinase pathways are examples of this family signaling pathway, which are
activated by TGF-β. These signaling pathways can cause a variety of cellular responses
including cell proliferation, apoptosis and differentiation (213). It has been demonstrated
that TGF-β can activate p38 MAPK signaling independent of Smads (214). Although the
exact mechanism of JNK, Erk or p38 MAPK activation by TGF-β is not well understood,
one possible mechanism for JNK and p38 MAPK activation is through the TGF-βactivated kinase 1 (TAK1) (215). TAK1 is one of the members of the MAPK kinase
kinases (MAPKKKs) family which are responsible for activation of JNK and p38 MAPK
in respond to a variety of stimuli such as TGF-β. It is also possible that TGF-β activates
the NF-kB signaling pathway because TAK1 is able to phosphorylate and activate IkB
kinase, which stimulates the NF-kB signaling. Further characterization of this network
will provide more details and insights into the MAPK activation by TGF-β.
TGF-β is also capable of activating Ras homolog gene-like (Rho-like) GTPases
including Rac, RhoA, RhoB, NET1 (RhoA-specific guanine exchange factor) and Cdc42
(216-219). These GTPases regulate many cellular events such as maintaining focal
contacts, contractile stress fibers and cell motility. It has been shown that RhoA and its
downstream signaling molecules such as p160ROCK have a critical role in the epithelial
to mesenchymal transition (EMT) induced by TGF-β (217).

1.2.5

Biological functions of TGF-β
TGF-β isoforms play important roles in many cellular processes. Most

importantly, TGF-β inhibits cell proliferation and regulates differentiation in different
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cell types (220). TGF-β inhibits cell proliferation by Smad2 and Smad3 transcriptional
program. Smads activate the expression of key cell cycle regulators such as CDK
inhibitors, p15 and p21 (221-224). Additionally, TGF-β downregulates the expression of
c-Myc. Downregulation of c-Myc results in induction of p15 and p21 expression (225,
226). The result of all these transcriptional changes is blocking the activities of CDKs,
which are required for the G1-S phase transition (Figure 1-1).
TGF-β is also responsible for mediating the expression of genes responsible for
ECM formation such as fibronectin, tissue inhibitors of metalloproteinases (TIMPs), PAI1, type I and type VII collagen (184, 227-230).
TGF-β is also a key player in EMT (231). EMT is a complex process in which
epithelial cells lose their cell-cell contacts, and begin to leave their community and spread
into surrounding tissues (232). TGF-β mediates EMT by regulating transcriptional
program of genes involved in this process such as Snail1, Twist1 and Cadherin-1(CDH1)
(233, 234). These transcriptional changes are coupled by the phosphorylation of PAR6
mediated by TβIIR to dissolve tight junctions and promote EMT (235).
Lastly, TGF-β1 null mice showed an excessive inflammatory response and
increased levels pro inflammatory cytokine such as TNF-α and interferon-γ. These data
suggest that TGF-β plays an important role in immune system by blocking pro
inflammatory chemokine synthesis (236, 237).
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1.2.6

Dual role of TGF-β in tumorigenesis
In the early stages of cancer initiation, TGF-β acts as a tumor suppressor similar

to its role in normal cells. However, in the later stages of cancer progression where
genetic interruptions of the TGF-β signaling pathway occur, cancer cells lose their
sensitivity to TGF-β mediated growth arrest. In this scenario, mutations of TGF-β
signaling components, which disturb TGF-β mediated growth arrest role is thought to,
cause a loss of proliferative control in cancer (142). However, it has been demonstrated
that many tumor cells, which lack any mutations in TGF-β signaling pathway
components also become refractory to TGF-β induced growth arrest and even, show
severe phenotype changes seen in EMT (238,239).
During cancer progression, crosstalk interactions of TGF-β pathway components
with altered oncogenic signalling affect transcriptional responses to TGF-β (240). For
instance, in pancreatic cancer cells with mutated Ras, the Smad3/TGF-β inducible
early gene two (TIEG2) complex loses its ability to downregulate the expression of cMyc resulting in loss of TGF-β growth inhibition (240). Further investigations have
revealed that the phosphorylation of TIEG2 by Erk prevents the binding of the Sin3A
corepressor to the c-Myc promoter, which results in loss of growth control by TGF-β
(241, 242). These studies suggested that the loss of Smad transcriptional responses is a
key event by which TGF-β loses its growth inhibitory role in cancer (141). Additionally,
TGF-β can promote tumor progression by inducing EMT through other signaling
pathways such as phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) signaling,
Notch signaling, RhoA, Rac1 and p38 MAPK (243, 216, 244).
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In summary, lose of TGF-β`s function as a tumor suppressor at later stages of
cancer progression through interactions with other oncogenic signaling pathways, leads
to changes in the transcriptional regulation of Smads and their interacting proteins and
induction of EMT. Since TGF-β plays a dual role in cancer, understanding of the exact
mechanisms by which TGF-β acts as a tumor suppressor or tumor promoters will provide
a great promise to develop new therapies for cancer patients with minimized unwanted
side effects. This thesis will focus on understanding of TGF-β growth controlling
mechanism to find better therapy for cancer patients.

1.2.7

Mouse models of TGF-β in development and cancer
To study the role and mechanism of TGF-β in development and cancer, a large

number of mouse models have been developed. This introduction briefly focuses on
gene-targeted disruptions of Smads and the gain and loss of function models of TGF-β
receptors and ligands.
To study the function of different TGF-β ligands and Smads, several knockout
mouse models were developed. These studies uncovered that TGF-β2 null mice have
several developmental defects such as cardiac, spinal and pulmonary defects (245). These
mice were also defective in processes such as ECM production, EMT and cell
proliferation (245). TGF-β3 null mice also showed defects in EMT and abnormal lung
development (246). Several knockout models of Smad proteins also have been developed
which provide more insights into the function of these proteins. Smad2 and Smad4 null
mice died early in the embryonic stage due to several developmental defects in
gastrulation and anterior-posterior axis formation (247-250). Surprisingly, Smad3
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knockout mice survived between 1-10 months after birth and then died due to the
impaired mucosal immune response, wound healing, and skeletal development (251-253).
Smad5 null mice also showed defects in angiogenesis and died at embryonic stage (254).
Multiple mouse models also have been developed to study mammary gland
development and cancer. Transgenic mice expressing an active form of TGF-β in
mammary epithelium, mouse mammary tumor virus (MMTV)-Tgf-β1223/225, showed a
hypoplastic mammary gland (255). In another study, mice expressing a dominantnegative form of TβIIR also showed increased ductal extension through the end bud
(256). These data suggest that TGF-β inhibits ductal growth and side branching during
mammary gland development.
Several studies have confirmed that TGF-β acts as a tumor suppressor in the
mammary gland. For instance, in mice expressing MMTV-Tgfβ1223/225, this active form
of TGF-β inhibited mammary tumor formation in 7-12-dimethylbenz (a) anthracene
(DMBA)-treated mice compared to DMBA-treated wild type controls (257). In contrast,
the dominant negative form of TβIIR in mouse mammary epithelium (MMTV-DNIIR)
increased the rate and number of tumor formation after treatment with the DMBA (258).
Furthermore, Mice expressing the active form of TGF-β under control of whey acidic
protein promoter (WAP-Tgfβ1223/225) introduced with MMTV during their pregnancy,
showed a decrease in the rate of tumor formation compared to control mice (256).
In addition to studies supporting the role of TGF-β as a tumor suppressor, there is
evidence that TGF-β also acts as a cancer promoter. One such evidence was seen in
transgenic mice expressing an activated TGF-β receptor in mammary gland (MMTV-
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TβRIAAV). These modifications inhibited Neu-induced tumorigenesis but increased lung
metastasis (259). Conversely, mice with the activated ligand under control of MMTV
promoter (MMTV-Tgfβ1223/225) did not affect tumor latency but enhanced tumor
invasiveness and metastasis to lungs (260).

1.3 Unique connection between LxCxE binding cleft and
TGF-β
As mentioned earlier, MEFs isolated from Rb1ΔL/ΔL mice have the ability to
maintain proliferative control in asynchronous growing cultures, in response to serum
starvation and confluence arrest (99). Furthermore, these mice are viable, fertile and able
to develop relatively normally but they show defects in mammary gland development
characterized by hyperplasia (261). The pups from female Rb1ΔL/ΔL animals were not
nursed regularly resulting in the neonatal lethality of animals raised by Rb1ΔL/ΔL mothers.
There was no defect in milk production, but milk was not ejected properly (261).
Interestingly, the mice hemizygous for tgf-β1 or mice expressing a dominant-negative
TβIIR show excessive ductal proliferation (262, 263). Furthermore, dominant-negative
TβIIR mice also display a nursing defect (264).
Since Rb1∆L mice and mice defective for TGF-β1 signaling within the mammary
epithelium have similar phenotype, this encouraged our lab to look at the ability of
Rb1∆L/∆L cells to respond to a TGF-β1 mediated growth inhibition. Our lab showed that
epithelial cells from Rb1∆L/∆L mice do not respond to TGF-β1 mediated growth arrest,
suggesting that the pRB-LxCxE interaction is necessary for TGF-β1-induced growth
arrest. Our lab also showed that TGF-β1 is able to induce the dephosphorylation and
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activation of mutant pRB and the defect in growth inhibition is downstream of pRB
activation (261). Our lab also showed that Rb1∆L/∆L mice are not able to repress E2F target
genes in response to TGF-β1 (261). This work suggested that the pRB-LxCxE interaction
plays a unique role in TGF-β1 growth inhibition.
In order to investigate the role of E2F transcription in TGF-β induced growth
arrest, our lab generated another knock-in mouse, called Rb1∆G. This mouse carries a
mutation that disrupts the interaction between pRB and E2F but its ability to bind to
LxCxE proteins is intact. Rb1∆G mice showed the same hyperplasic phenotype as the
Rb1∆L mutants and they were defective in response to TGF-β1 mediated growth arrest.
This confirms that E2F regulation by pRB is a requirement in TGF-β induced growth
arrest. Taken together, these data show that a repressor complex including pRB, one or
more LxCxE motif containing co-repressor(s) and an E2F transcription factor is involved
in TGF-β growth inhibition. Since the exact LxCxE interacting protein(s) that cooperate
with pRB in TGF-β growth arrest paradigm is unclear, it is logical to search for LxCxE
motif containing proteins that cooperate with pRB in E2F transcriptional repression in
response to TGF-β to understand how TGF-β inhibits cell proliferation.
To identify candidates that bind to pRB through the LxCxE binding cleft, our lab
performed a Glutathione S-transferase (GST) pull down screen. In order to perform GST
pull-downs, nuclear extracts from HeLa cells were mixed with GST-RBWT and GSTRB∆L proteins. Bound proteins were resolved by SDS-PAGE and silver stained. The data
showed that numerous proteins were missing from GST-RB∆L. These bands were
subjected to Mass Spectrometry and western blotting analysis identified some of these
proteins. Taken together, pRB could interact with four major complexes including
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anaphase-promoting complex (APC), Sin3, NuRD and CtBP through the LxCxE binding
cleft (99, 265). Since APC regulates proliferation independently of E2F, we did not
include this complex in our research (265). All components of three potential complexes
are shown in Table 1-1 (266-268, 135).

1.4 Thesis hypothesis and objectives
The majority of proteins with LxCxE motif have been reported to bind to pRB
before RNAi technology and as a result, there is no evidence of the requirement of
LxCxE motif containing proteins in cell cycle arrest under physiological conditions.
Thus, we are searching for proteins reported to bind to pRB through the LxCxE binding
cleft but lack verification in a physiological setting. It is interesting to mention that
whether these proteins directly or indirectly bind to the LxCxE binding cleft is unclear.
Based on the evidence from literature and experiments done in our lab, the
hypothesis of this study is that pRB interacts with specific repressor complexes
through the LxCxE binding cleft to repress E2F dependent transcription in
response to TGF-β and this function is important for cancer suppression.
Objective: Identification of proteins cooperating with pRB in E2F transcriptional
repression in response to TGF-β
To identify proteins cooperating with pRB in response to TGF-β, lentiviral
vectors carrying short hairpin RNA (shRNA) were used. Using these shRNAs, we
depleted the expression of each component and examined if depletion of these
components compromises TGF-β mediated growth arrest. This experimental approach
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will identify complexes such as Sin3, NuRD and CtBP, which cooperate with pRB in
E2F transcriptional repression in response to TGF-β.
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2

Materials and Methods
2.1 Cell lines and cultures
MCF-10A cells were a generous gift from Gabriel Dimattia lab (Western

University). The original MCF-10 cell line was isolated from mastectomy performed on a
36-year-old woman (269). From the original diploid mortal cell, MCF-10A cells, a
spontaneously immortal subline of MCF-10, have been derived after extending trypsin
passages in the normal calcium levels (1.05 mM). MCF-10A cells have characteristic
features of normal mammary epithelial cells and are sensitive to TGF-β mediated growth
arrest (269).
MCF-10A cells were grown in Dulbecco's modified Eagle's Medium-Ham`s F12
(DMEM-F12) (Invitrogen, Cat # 11320-033). DMEM-F12 was supplemented with 20
ng/ml Epidermal Growth Factor (EGF) (Sigma, Cat # E9644), 5% horse serum (Gibco,
Cat# 26050-088), 0.5 mg/ml hydrocortisone (Sigma, Cat # H4001), 10 g/ml insulin
(Sigma, Cat # I6634), 100 ng/ml cholera toxin (Sigma, Cat# C8052) and 1%
penicillin/streptomycin (Gibco, Cat #15070-063) at 37°C in a 5% CO2 humidified
incubator.
Routine passaging of these cells involved aspirating the growth medium and
washing the cells with Phosphate Buffered Saline (PBS) (Sigma, Cat # P3813), adding
trypsin solution and incubating them in a 5% CO2 humidified incubator at 37°C. Once
cells were dislodged by gently tapping and trypsin incubation, growth medium was added
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to neutralize the trypsin. The cells were then spun down in a 15 ml conical tube and were
split in 1:5 ratios.

2.2 ShRNA transfection
HEK 293T cells were a generous gift form Joe Mymryk lab (Western
University). HEK 293T cells were plated at a density of 7×105 cells in 5 ml of DMEM +
10% FBS without antibiotics (no penicillin/streptomycin) media in a 6 cm plate the day
before the transfection. The following morning, the media was changed to a fresh media
without antibiotics and in the late afternoon, cells were transfected with lentiviral shRNA
plasmids. To transfect the cells, 6 μg shRNA plasmid (Open Biosystems), 3 μg psPAX2
packaging plasmid, 3 μg pMD2.G envelope plasmid (Addgene #12259 and 12260) and
up to 20 μl serum-free OPTI-MEM media (Gibco, Cat # 31985-062) was added to a
microcentrifuge tube. In another tube, 74 μl serum-free OPTI-MEM and 6 μl FuGENE
transfection reagent (Roche Applied Biosciences) was added, mixed and incubated at
room temperature. After 5 minutes of incubation, 80 μl FuGENE master mix from the
second tube was added to the first tube to make a total 100 μl master mix and then
incubated at room temperature. After 15 minutes, the mix was added dropwise to the
plate and the cells were incubated at 37°C in a 5% CO2 incubator for 15 hours. The
following morning, the media was replaced with 3 ml fresh DMEM + 10% FBS +
penicillin/streptomycin and incubated for 48 hours to produce lentiviral particles.
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Table 2-1 List of the shRNAs used in knockdown experiments (Open
Biosystems)

Target

Antisense Sequence

Vector

NM_000321 TRCN0000040163

TTTGGACTAGAAATAATGTGG

pLKO.1

NM_000321 TRCN0000040164

TTGCAGTAGAATTTACACGCG

pLKO.1

NM_000321 TRCN0000040165

TTCACAAAGTGTATTTAGCCG

pLKO.1

SAP30

NM_003864 TRCN0000021687

AACACCACTATCAACCTTGAG

pLKO.1

MTA2

NM_004739 TRCN0000013374

TATCTGTCTCATTCAAGAGGG

pLKO.1

SAP18

NM_005870 TRCN0000021660 AAACCCAGGGCTGCCTTGGAAAAG pLKO.1

gene

Accessions

Clone ID

RB1
(shRB#1)
RB1
(shRB#2)
RB1
(shRB#3)
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2.3 Lentiviral Infection
To infect MCF-10A cells with lentiviral particles, the media from HEK 293T
cells transfected with lentiviral shRNA was filtered through a 0.45 µm filter after 48
hours transfection and supplemented with 8 µg/mL of Polybrene (Sigma, Cat # H9268) to
increase the efficiency of viral infection. The filtered media, which contains lentiviral
particles, was directly added to MCF-10A cells that had been plated the previous day at
density of 3×105 cells in a 6 cm dish. MCF-10A cells were incubated for 24 hours in the
incubator. Next morning, the media was replaced with a fresh media. After 24 hours, the
media from MCF-10A cells was removed and puromycin was added to the cells at a final
concentration of 1.6 µg/ml. The culture was replaced with media containing puromycin
every other day. One uninfected plate of cells in parallel was treated with puromycin to
serve as a positive control for the puromycin selection. Infected MCF-10A cells were
then expanded for further experiments.

2.4 TGF-β1 preparation and treatment
To make TGF-β1 (R&D systems, Cat # 240-B-010) stock solution, 30%
acetonitrile/0.1% trifluoroacetic acid (TFA) solution was made and filtered through a
0.22 µm filter. TGF-β1 powder was diluted with the above solution to a 0.1 M stock
concentration and aliquoted to several microcentrifuge tubes. Filled tubes were placed at
-20°C overnight, and then transferred to -80°C for long-term storage.
TGF-β1 was used at a final concentration of 100 pM. The stock was then stored at
4°C after usage and used within a few weeks.
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2.5 5-bromo-2-deoxyuridine (BrdU)-propidium iodide (PI)
staining
MCF-10A cells were labeled with BrdU and PI as previously described (270). 1
µl of Cell Proliferation Labeling Reagent (BrdU) (GE Healthcare, Cat # RPN201) was
added for each ml of cell culture medium (1 to 1000 dilutions) and incubated at 37°C.
After 4 hours of incubation, the cells were washed with PBS and trypsin was added to
dislodge the cells. Once MCF-10A cells dislodged, they were transferred to a 15 ml
conical tube and spun down at 500 g for 5 minutes. The cells were washed with PBS one
more time and then resuspended in 100 μl PBS. Then, 1 ml of 95% EtOH was added
dropwise while vortexing to fix the cells and incubated for 30 minutes in 4°C. After
fixing the cells, EtOH was removed and 1 ml of 2N HCl/0.5% Tx-100 was added in a
dropwise fashion while vortexing and the cells were incubated at room temperature for
30 minutes. To neutralize HCl, 1 ml of 0.1 M NaB4O7 (pH 8.5) was gently added after
removing HCl from cell pellet. After 30 minutes incubation at room temperature, the cell
pellet was resuspended in 0.5 ml of antibody solution (PBS containing 0.2% Tween-20
and 1% BSA) with mouse anti-BrdU antibodies (BD Biosciences, 347580) diluted 1 to 25
and incubated at room temperature for 30 minutes in dark. The cells were pelleted and
resuspended in 50 µl of antibody solution containing rabbit anti-mouse secondary
antibodies conjugated to fluorescein isothiocyanate (FITC) (Vector Laboratories, Cat #
FI-2000) diluted 1 to 10 and incubated for 30 minutes at room temperature in dark.
Finally, cells were resuspended in 0.5 ml of PI and RNase A solution (PBS with
1% BSA, 1 mg/ml PI, 0.25 mg/ml RNase A) and incubated in dark at 37°C for 30
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minutes. The solution was passed through a cell strainer to remove cell clumps before
running the samples on flow cytometer.

2.6 Flow cytometry analysis
After staining MCF-10A cells with PI and BrdU, cell populations were analyzed
by flow cytometry on a Beckman-Coulter EPICS XL-MCL instrument, which is capable
of detecting PI and FITC. The sensitivity of photomultiplier tubes for PI and FITC was
adjusted such that 2N and 4N peaks are centered at 200 and 400 (arbitrary units) on the
X-axis for PI plot and BrdU positive cells are approximately 10 times brighter for FITC
plot. Finally, 5000 to 10000 single cell events were collected for each sample in order to
ensure that results obtained are representing the cells cultured in each plate.

2.7 Preparation of nuclear extract from cells
To generate nuclear extracts, MCF-10A cells were washed twice with PBS and
collected into 1 ml of PBS with cell scrapers. Collected cells were centrifuged at 200 g
for 5 minutes at 4°C and supernatant was removed. The pellet was resuspended in 200 µl
of Hypotonic Lysis Buffer (HLB) (10 mM Tris pH 7.5, 10 mM KCl, 3 mM MgCl2 and 1
mM EDTA). HLB was supplemented with the protease inhibitors cocktail (1 mM DTT, 1
mM PMSF, 5 mM NaF, 0.1 mM Na3VO4, 5 µg/ml Leupeptin and 5 µg/ml Aprotinin) and
incubated on ice for 5 minutes. NP-40 was added to each sample for a final concentration
of 0.05% and incubated for 5 minutes on ice. The lysate was centrifuged at 1800 g for 10
minutes, supernatant was then removed and 200 µl HLB supplemented with protease
inhibitors cocktail and 0.05% NP-40 was added to pellet and resuspended lysate was
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incubated for 10 minutes on ice. This was repeated three more times. Then, the pellet was
resuspended in 100 μl Gel Shift Extract (GSE) buffer (20 mM Tris pH 7.5, 420 mM
NaCl, 1.5 mM MgCl2 and 0.2 mM EDTA and 25% Glycerol) supplemented with the
protease inhibitors cocktail (25 mM DTT, 0.5 mM NaF, 0.1 mM Na3VO4, 0.1% NP-40, 5
µg/ml Leupeptin and 5 µg/ml Aprotinin). Extracts were frozen and kept at -80°C. Finally,
extracts were thawed and cellular debris was removed by centrifugation at 21000 g for 20
minutes when they were used for protein concentration measurement.

2.8 Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and western blotting
SDS-polyacrylamide gels were prepared in mini gel. Resolving gel mix was
prepared according to the volume required for making 10% SDS-polyacrylamide gels,
added in the gel apparatus and EtOH was poured to the top. Clear distinction between
EtOH and gel indicates the gel has dried. EtOH was poured out, and immediately
stacking gel was poured in, and the comb was inserted and allowed to solidify at room
temperature. 30-50 µg protein samples were mixed with 5× sample buffer (0.225 M TrisHCl pH 6.8, 5% SDS, 50% Glycerol, 0.05% bromophenol blue and 0.25 M DTT) and
denatured by heating at 95°C for 5 minutes, glass plates (with solidified gel) were locked
into the gel electrophoresis cassette and the electrophoresis cassette was placed into SDSPAGE apparatus. The inner chamber was filled with 1× SDS-PAGE running buffer and
the outer chamber was filled half way with the same buffer. Protein samples were loaded
into the wells and electrophoresed at constant current at 120 V for 1.5 hours.
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SDS-PAGE gel was transferred onto nitrocellulose membrane at 500 mA for 60
minutes at 4°C. The transferred membrane was incubated in a blocking solution (3% fat
free milk in 1×TBS-Tween (200 mM Tris pH 7.5, 1.5 M NaCl, 3% Tween-20)) for one
hour at room temperature while shaking. Membrane was directly incubated in primary
antibodies overnight at 4°C while shaking. After incubation, the membrane was washed
in 1X TBS-Tween for 10 minutes for three times. Then, the membrane was incubated in
horseradish peroxidase (HRP) conjugated secondary antibodies against mouse or rabbit
antibody for one hour at 25°C and then washed in 1 X Tris-buffered saline (TBS)-Tween
for two times and 5 minutes each. Proteins were visualized with
chemiluminescent detection method.
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Table 2-2 List of the antibodies used for western blotting and staining

Antibody

Protein

Host

Dilution

Name

Recognized

Species

sc-6200

Smad2

Goat

Santa Cruz

1:500

Rabbit

Chemicon

1:700

Mouse

BD-Bioscience

1:25

Company
ratio

Phospho-specific
AB3849

Smad2
(Ser465/467)

347580

BrdU
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2.9 RNA isolation
Total RNA was isolated using GenEluteTM Mammalian total RNA miniprep kit
(Sigma, Cat # RTN70-1KT). Before beginning the procedure, the lysis solution/2mercaptoethanol (2-ME) mixture was prepared by adding 10 µl of 2-ME to each ml of
lysis solution that was sufficient for the same day use. In addition, the concentrate wash
solution 2 was diluted with 100% EtOH in ratio 1:4 (1 part concentrate wash solution 2: 4
parts 100% EtOH).
To extract RNA from MCF-10A cells plated in a 6 cm plate, cells were washed
with PBS twice and then PBS was removed completely. To lyse cells, 250 µl lysis
solution/ 2-ME mixture was directly added to the plate and incubated for 3 minutes at
room temperature. Then, the plate was titled to collect the lysate. The lysed cells were
transferred into a GenElute Filtration Column (blue insert with a 2ml receiving tube) and
centrifuged at maximum 12000 g for 2 minutes to remove cellular debris and shears
DNA. Then, the filtration column was discarded and the receiving tube was kept. An
equal volume of 70% EtOH was added and mixed with the filtered lysate by vortexing.
The lysate/EtOH mixture was loaded into GenElute Binding Column (colorless insert
with a red o-ring seated in a 2 ml receiving tube) and centrifuged at 12000g for 15
seconds. The flow through liquid was discarded but the collection tube was retained.
Then, 500 µl of wash solution 1 was added into the column and centrifuged at 12000 g
for 15 seconds. The binding column was transferred into a fresh 2 ml collection tube and
flow-through liquid and the original collection tube were discarded. 500 µl of diluted
wash solution 2 was loaded into the column and centrifuged at 12000 g for 15 seconds.
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The flow-through liquid was discarded but the collection tube was retained. This step was
repeated but the column was centrifuged for three more minutes to dry. Finally, the
binding column was transferred to a fresh 2 ml collection tube and 50 µl elution solution
was then loaded into the binding column and centrifuged at 12000 g for one minute. The
quality and quantity of RNA were evaluated by measuring OD 260/280 and 260/230
ratio. Purified RNA in the collection tube was stored at -80°C.

2.10 Generation of total cDNA
The total complementary DNA (cDNA) was generated using SuperScript® III
Reverse Transcriptase kit (Invitrogen, Cat # 18080-044). 1 µg RNA and up to a total
volume of 10 µl RNase free H2O was added to an RNase free PCR tube. 1 µl DNase I
and 1 µl 10× DNase I reaction buffer was added to the PCR tube and the sample was
incubated at room temperature for 15 minutes to degrade all genomic DNA. The reaction
was stopped by adding 1 µl 25 mM EDTA, 1 µl of 10 mM dNTP mixture and incubating
at 70°C for 5 minutes. Then, the reaction mixture was prepared in a total volume of 9 µl
by adding 4 µl of 5× First Strand buffer, 2 µl of 100 mM dithiothreitol (DTT), 1 µl 50µM
oligo (dT) 20, 1 µl RNase OUT™ (40 U/µl) and 1 µl of SuperScript® III Reverse
Transcriptase (250 U/µl). In addition to this mixture, one mixture without SuperScript®
III Reverse Transcriptase was made to serve as a control. The reaction mixture was
gently vortexed and added to the sample. The final mixture was incubated for the
following times: 5 minutes at 25°C, 40 minutes at 42°C, 30 min at 50°C, 40 minutes at
55°C and finally 15 minutes at 70°C. The generated cDNA was diluted in RNase free
H2O for downstream application.
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2.11 Real-Time PCR
Real-time PCR was performed by the fluorescent dye SYBR Green methodology
using the iQTM SYBR® Green Supermix (Bio-Rad, Cat # 170-8880). To perform RealTime PCR, the following master mix was prepared for each reaction: 5 µl iQTM SYBR®
Green Supermix, 1 µl forward primer, 1 µl reverse primer and up to 8 µl H2O. 2µl of
cDNA prepared by SuperScript® III Reverse Transcriptase system was added to each
master mix. Finally, the samples were run on a CFX96 Touch™ real-time PCR detection
system (Bio-Rad). Each reaction included GAPDH as a reference gene for normalization,
and reactions lacking cDNA served as negative controls. The primers used in Real-Time
PCR and RT-PCR are in the following table. (Table 2-3)
To calculate the gene expression, Ct values for all genes were acquired in all
samples. To normalize the expression of each target genes, the difference between
GAPDH and target gene Ct values was calculated for each sample. Then, the relative
expression of each target gene was calculated using the following formula in each
sample: 2 (CtGAPDH –Cttarget gene). Finally, to determine the fold change expression of the
target gene, the relative expression of the target gene in each sample was divided by its
relative expression in the calibrator sample (Untreated shLuc in our case).
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Table 2-3 List of the primers used for Real-Time PCR

Gene

Forward Primer

Reverse Primer

RB1

GCATGGCTCTCAGATTCACCT

CTTCTGGGTCTGGAAGGCTG

SAP30

AAGAGCGCAAGGCATCTTTA

GTCCTGGTCTGGTTGGTAGC

MTA2

TGGTTAGACGGATTGAGGAGC

GCGCCGGAAAAGACAGACA

SMAD7

TTCCTCCGCTGAAACAGGG

CCTCCCAGTATGCCACCAC

GAPDH

GCCGCATCTTCTTTTGCGTC

GATCTCGCTCCTGGAAGATGG

PCNA

TCCTGTGCAAAAGACGGAGT

TCTACAACAAGGGGTACATCTGC

CCNE1

GCCAGCCTTGGGACAATAATG

AGTTTGGGTAAACCCGGTCAT

CCNA2

CCTGGACCCAGAAAACCATTG

ATTTAACCTCCATTTCCCTAAGGT

SAP18

CCTCGCGAGAGACTTAGTGC

AAGACCCGTAGCAACAGTGG
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2.12 Statistical analysis
Each experiment was repeated three times. Values are shown as the mean ±
standard deviation (SD) of triplicate measurements. Student’s paired t-test was used to
analyze differences between the sample of interest and its control. A p value of less than
0.05 was considered statistically significant.
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3

Results
3.1 Identification of proteins cooperating with pRB in E2F
transcriptional repression in response to TGF-β

3.1.1

Rationale
As mentioned earlier, our experiments using the Rb1∆L mouse model uncovered

that the LxCxE-pRB interaction plays an essential role in TGF-β growth inhibition. The
exact LxCxE interacting protein(s) that cooperate with pRB in TGF-β growth arrest
paradigm is unclear. Therefore, it is logical to search for LxCxE motif containing
proteins that cooperate with pRB in E2F transcriptional repression in response to TGF-β
to understand how TGF-β inhibits cell proliferation.
Previous experiments in our lab showed that four complexes including APC,
Sin3, NuRD and CtBP interact with pRB in an LxCxE dependent manner (99, 265).
Lentiviral vectors carrying short hairpin RNA (shRNA) was used to deplete the
expression of components of each complex in order to identify components cooperating
with pRB in E2F transcriptional repression in response to TGF-β.
A difficulty in this screen is that some components have different isoforms such
as Sin3A/B, Mi2α/β that share functional and structural similarities, so their function in
cooperation with pRB may be redundant. In addition, some components are common
between different complexes such as HDAC1/2, RbAp46/78 and lysine specific
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demethylase 1 (LSD1). This makes them less desirable to start the screening. Therefore,
the screening was started with some unique components of these complexes.

3.1.2

TGF-β growth arrest is pRB dependent in MCF-10A cells
Previous experiments in our lab showed that MEFs from LxCxE mutant mice

were unresponsive to TGF-β mediated growth arrest. Our lab also analyzed TGF-β
growth control in primary mouse epithelial cells (MECs) and keratinocytes, which are
more sensitive to TGF-β mediated cell cycle arrest. Both cell types isolated from LxCxE
mutant mice showed the same defect in response to TGF-β mediated growth inhibition
(261). Isolation of MECs or keratinocytes requires many mice, therefore, MCF-10A cells,
a normal human mammary epithelial cell, were used for the growth arrest experiments.
TGF-β1 mediated growth inhibition in mouse fibroblast requires pRB (271);
therefore, we wanted to ensure that TGF-β1-induced growth arrest is pRB dependent in
MCF-10A cells. To do this, 3×105 MCF-10A cells were plated in 6 cm plates in
duplicate. Then, these cells were infected with lentiviral vector carrying shRNA to
deplete the expression of pRB along with shRNA expressing luciferase (shLuc) as a
control. After infection and three days of selection with puromycin, the infected cells
were expanded for further experiments.
To confirm knockdown efficiency, 4×105 infected MCF-10A cells were plated in
6 cm plates in duplicate for each shRNA and treated one plate of each shRNA with TGFβ1 (100 pM) for 24 hours. After treatment with TGF-β1, RNA was isolated and
converted to cDNA and Real-Time PCR was performed for pRB to confirm knockdown
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efficiency. As shown in Figure 3-1A, the level of pRB transcript was significantly
reduced in MCF-10A cells.
To perform growth arrest assays, 4×105 infected MCF-10A cells were plated in 6
cm plates in duplicate for each shRNA. TGF-β1 (100 pM) was added to one plate of each
shRNA. After 24 hours TGF-β1 treatment, the cells were pulse-labeled with BrdU for 4
hours. Then, the percentage of cells with incorporated BrdU was quantified by flow
cytometry. As shown in Figure 3-1B, MCF-10A cells expressing shLuc showed a
significant decrease in BrdU incorporation in response to TGF-β1 whereas pRB depleted
cells did not respond to TGF-β1-induced growth arrest. This suggests that depletion of
pRB compromises TGF-β-induced growth arrest. To avoid off-target effects, the same
experiment was repeated with two more shRNAs targeting pRB and they all showed the
same results. In conclusion, these results show that TGF-β1-induced growth arrest is pRB
dependent in MCF-10A cells, because multiple shRNAs against pRB can interrupt TGFβ1-induced growth arrest in these cells.
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Figure 3-1 TGF-β1-induced growth arrest is pRB dependent in MCF-10A cells
(A) MCF-10A cells were infected with shRNA to deplete the expression of pRB. After
infection and three days selection, the infected cells were treated with TGF-β1 for 24
hours. The mRNA level of pRB was measured by Real-Time PCR to verify knockdown
efficiency. All values for Real-Time PCR experiments were normalized to the level of
GAPDH mRNA abundance. (B) The depleted cells were treated with TGF-β1 for 24
hours and pulse-labeled with BrdU for 4 hours. The percentage of cells incorporating
BrdU was measured by flow cytometry. The average of three independent experiments is
shown. The asterisks indicate a statistically significant difference from untreated shLuc
(Student's t test; P < 0.05). The error bars indicate one standard deviation from the mean.
(+ve, positive)
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3.1.3

E2F target genes are deregulated upon pRB depletion in
response to TGF-β
A recent study has shown that the TGF-β signaling pathway is regulated by

multiple microRNAs (miRNAs) (272). A large-scale RNAi screen was performed to
identify novel components and modulators of the TGF-β pathway by looking at the
nuclear translocation of a green fluorescent protein (GFP)-Smad2 fusion protein. It was
identified that 176 siRNAs inhibit nuclear localization of Smad2 in response to TGF-β.
However, after finding genes correlating to each siRNA hit, they were not able to group
these genes in any relevant biological process nor were any of these genes relevant to any
genes involved in the TGF-β pathway. Further analysis revealed that these selected hits
would significantly reduce mRNA levels of TGF-β receptors (TβRs), particularly TβIIR
through miRNA off-target effects. It has been demonstrated that complementarity
between a heptamer or hexamer ‘seed’ match of siRNA and 3’ untranslated region (UTR)
of an off-target gene mediates the off-target effects observed in siRNA screens (273,
274). This was confirmed by sequence analysis of siRNA and 3’ UTR of TβIIR in their
study. Thus, the risk of obtaining misleading results using shRNA in single-assay readout
is substantial. Therefore, control experiments are essential in the interpretation of such
results.
To ensure that the TGF-β1-induced growth arrest in our knockdown experiments
is not a result of TβIIR down regulation or its disability to act on Smads, western blotting
was performed to look at phosphorylation of Smad2. To do this, 2.8×107 pRB depleted
MCF-10A cells were plated in 15 cm plates in duplicate along with shLuc MCF-10A
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cells and then TGF-β1 (100 pM) was added to one plate of each shRNA for 24 hours.
After treatment with TGF-β1, the nuclear extract was isolated and was blotted for
phospho-Smad2. As shown in Figure 3-2A, TGF-β1 stimulation of MCF-10A cells
resulted in phosphorylation of Smad2 in all pRB knockdown cells similar to control cells
suggesting that the expression and activity of TGF-β1 receptor is intact after pRB
knockdown by shRNAs.
It has been shown that pRB binds to E2F transcription factors and represses the
transcription of E2F responsive genes and loss of pRB results in a deregulation of E2F
target genes expression (275). Thus, the transcript levels of E2F targets were examined to
investigate if they are repressed in TGF-β1 mediated growth arrest and if this effect is
disrupted by pRB depletion. To do this, pRB depleted and shLuc MCF-10A cells were
treated with TGF-β1 for 24 hours, RNA was then isolated and converted to cDNA and
Real-Time PCR was performed for two E2F responsive genes. As shown in Figure 3-2B,
E2F target genes, CCNE1 and CCNA2, are repressed in response to TGF-β1 in shLuc
MCF-10A cells and this repression is disrupted after depletion of pRB. Based on these
analyses, further experiments were performed to knockdown the expression of
components of complexes, which can bind to pRB through the LxCxE binding cleft.
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Figure 3-2 The TGF-βsignalingisintactandE2F target genes repression is
disrupted by pRB depletion
(A) Total phospho-Smad2 expression levels were measured in pRB depleted and shLuc
MCF-10A cells by western blot analysis. The upper band is phospho-Smad2 and the
asterisk indicates the non-specific lower band. (B-C) Total RNA from MCF-10A cells
infected by shLuc and shRB #2 was isolated using GenElute Mammalian Total RNA
Purification Kit. To eliminate DNA genomic contamination, RNA was digested by
DNAse1 and then cDNA was generated using Superscript III. The average of three
independent experiments is shown. The asterisks indicate a statistically significant
difference from untreated shLuc (Student's t test; P < 0.05). The error bars indicate one
standard deviation from the mean. All values for Real-Time PCR experiments were
normalized to the level of GAPDH mRNA abundance.
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3.1.4

SAP18, a unique component of the Sin3 complex
SAP18 is another core protein in the Sin3 complex. SAP18 protein directly

interacts with both mammalian Sin3 and HDAC1 (116). It has been suggested that
SAP18 may have a potential role in stabilizing the HDAC1-Sin3 interaction and
enhancing HDAC1 enzymatic activity (116). Furthermore, SAP18 can interact with other
proteins of various transcriptional regulatory circuits (116). It has been shown that one of
the mechanisms by which E2F-pRB mediates repression of E2F target genes is through
the recruitment of HDAC (38). Therefore, SAP18 may have a role in TGF-β1 mediated
growth arrest. This motivated us to examine the role of SAP18 in TGF-β1 mediated
growth arrest.

3.1.4.1

SAP18 is not involved in TGF-β1 mediated growth arrest

To examine whether SAP18 is involved in TGF-β1-induced growth arrest, 3×105
MCF-10A cells were plated in 6 cm plates in duplicate. Then, these cells were infected
with lentiviral vector carrying SAP18 shRNA along with shCtrl as a control. After
lentiviral infection and selection with puromycin, the infected cells were expanded for
further experiments.
To confirm knockdown efficiency, 4×105 infected MCF-10A cells were plated in
6 cm plates in duplicate for each shRNA. TGF-β1 (100 pM) was added to one plate of
each shRNA for 24 hours. RNA was isolated and converted to cDNA and Real-Time
PCR was performed for SAP18. As shown in Figure 3-6A, the level of SAP18 transcript
was significantly reduced in MCF-10A cells.
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To do TGF-β1 growth arrest assay, 4×105 infected MCF-10A cells were plated in
6 cm plates in duplicate for each shRNA and TGF-β1 (100 pM) was added to one plate of
each shRNA. After 24 hours TGF-β1 treatment, cells were pulse-labeled with BrdU for 4
hours. Then, flow cytometry was performed to quantify the number of cells incorporating
BrdU. As shown in Figure 3-3B, both MCF-10A cells expressing shCtrl and shSAP18
showed a significant decrease in BrdU incorporation in response to TGF-β1. This
suggests SAP18 is not involved in TGF-β1-induced growth arrest.
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Figure 3-3 Depletion of SAP18 does not compromise TGF-β1 mediated
growth arrest
(A) MCF-10A cells were infected with shRNA to deplete the expression of SAP18.
After infection and three days selection, the infected cells were treated with TGF-β1 for
24 hours, the mRNA level of SAP18 was measured by Real-Time PCR to verify
knockdown efficiency. All values for Real-Time PCR experiments were normalized to
the level of GAPDH mRNA abundance. The asterisks indicate a statistically significant
difference from untreated shCtrl (Student's t test; P < 0.05). The error bars indicate one
standard deviation from the mean. (B) The depleted cells were treated with TGF-β1 for
24 hours and pulse-labeled with BrdU for 4 hours. The percentage of cells incorporating
BrdU was measured by flow cytometry. The average of three independent experiments is
shown. The asterisks indicate a statistically significant difference from untreated samples
(Student's t test; P < 0.05). The error bars indicate one standard deviation from the mean.
(+ve, positive)
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SAP30, a potential component involved in TGF-β growth

3.1.5

arrest
SAP30 is one of the unique components of Sin3 complex (112). SAP30 directly
interacts with HDAC1 and multiple subunits of the Sin3 complex suggesting that SAP30
may play a role in stabilizing the complex (112). It has been demonstrated that pRB can
repress transcription of E2F target genes through the recruitment of HDAC, which
removes the acetyl groups of positive charge residues from histones on the promoter,
thereby promoting the formation of closed nucleosomes that inhibit transcription (51).
Therefore, it is logical to look for unique components, which associate with HDACs in
potential complexes. Since SAP30 interacts with HDAC1, this motivated us to examine
the ability of MCF-10A cells to respond to TGF-β in absence of SAP30.

3.1.5.1

Depletion of SAP30 compromises TGF-β growth arrest

To examine whether SAP30 is involved in TGF-β growth inhibition, 3×105 MCF10A cells were plated in 6 cm plates in duplicate. Then, these cells were infected with
lentiviral vector carrying shRNA to deplete the expression of SAP30 along with shLuc as
a negative control. After infection and three days of selection with puromycin, the
infected cells were expanded for TGF-β1-induced growth arrest assays and knockdown
efficiency.
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To examine knockdown efficiency, 4×105 infected MCF-10A cells were plated in
6 cm plates in duplicate for each shRNA and one plate was treated with TGF-β1 (100
pM) for 24 hours. After treatment with TGF-β1, RNA was isolated and converted to
cDNA and Real-Time PCR was performed for SAP30. As shown in Figure 3-4A, the
level of SAP30 transcript was significantly reduced in MCF-10A cells.
To examine the role of SAP30 in TGF-β growth inhibition, 4×105 infected MCF10A cells were plated in 6 cm plates in duplicate for each shRNA and TGF-β1 (100 pM)
was added to one plate of each shRNA. After 24 hours TGF-β1 treatment, the cells were
pulse-labeled with BrdU for 4 hours and then the percentage of cells incorporating BrdU
was quantified by flow cytometry. As shown in Figure 3-4B, MCF-10A cells expressing
shLuc showed a significant decrease in BrdU incorporation in response to TGF-β1
whereas the ability of SAP30 depleted cells to induce TGF-β1 growth arrest was reduced.
This suggests that depletion of SAP30 compromises TGF-β1-induced growth arrest.
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Figure 3-4 Depletion of SAP30 compromises TGF-β1 mediated growth arrest
(A) MCF-10A cells were infected with shRNA to deplete the expression of SAP30.
After infection and three days selection, the infected cells were treated with TGF-β1 for
24 hours; the mRNA level of SAP30 was measured by Real-Time PCR to verify
knockdown efficiency. All values for Real-Time PCR experiments were normalized to
the level of GAPDH mRNA abundance. (B) The depleted cells were treated with TGF-β1
for 24 hours and pulse-labeled with BrdU for 4 hours. The percentage of cells
incorporating BrdU was measured by flow cytometry. The average of three independent
experiments is shown. The asterisks indicate a statistically significant difference from
untreated shLuc (Student's t test; P < 0.05). The error bars indicate one standard deviation
from the mean (+ve, positive).

70

3.1.5.2

TGF-β signaling is intact in absence of SAP30

The mechanism by which SAP30 depletion disrupts TGF-β1-induced growth
inhibition was then investigated. In the presence of the TGF-β ligand, the TβIIR receptor
phosphorylates the TβIR. This phosphorylation allows TβIR to phosphorylate and
activate Smad2/3 proteins. After Smad2/3 activation, they bind to Smad4 proteins and
then this complex translocates to the nucleus. Once in the nucleus, this complex binds to
specific regions of the genome along with other co-repressors or co-activators to regulate
gene transcription, which ultimately leads to G1 growth arrest (146). To determine
whether SAP30 is involved in TGF-β1-induced growth inhibition and to ensure that
shRNA targeting SAP30 transcript is not downregulating TβIIR level leading to growth
arrest observed in knockdown experiment, the TGF-β signaling pathway in SAP30
depleted cells was analyzed. To do this, 2.8×107 SAP30 depleted MCF-10A cells were
plated in 15 cm plates in duplicate along with MCF-10A cells infected by shLuc as
control and treated one plate of each with TGF-β1 (100 pM) for 24 hours. After treatment
with TGF-β1, nuclear extract was isolated and was blotted for phospho-Smad2. As
shown in Figure 3-5A, Smad2 proteins are phosphorylated in response to TGF-β1 in
SAP30 depleted MCF-10A cells in the same manner as shLuc MCF-10A cells. This
suggests that depletion of SAP30 does not block TGF-β1 receptor expression and
function.
Phosphorylated Smads along with other cofactors can activate transcription of
several genes such as Smad7 (211). To investigate the effect of SAP30 depletion on
Smad-dependent transcription, the ability of SAP30 depleted MCF-10A cells were
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examined in transcriptional activation of Smad7 in response to TGF-β1. To do this, 4×105
SAP30 depleted MCF-10A cells were plated in 6 cm plates in duplicate along with shLuc
MCF-10A cells and treated one plate of each shRNA with TGF-β1 (100 pM) for 24
hours. After treatment with TGF-β1, RNA was isolated and converted to cDNA and
Real-Time PCR was performed for Smad7. As shown in Figure 3-5B, Smad complexes
are able to activate transcription of Smad7 in the absence of SAP30 suggesting that
Smad-dependent transcription is intact in the absence of SAP30.

72

A

B

73

Figure 3-5 TGF-βsignalingisintactinabsenceofSAP30
(A) The total phospho-Smad2 expression level was measured in TGF-β1-treated and
untreated SAP30 depleted MCF-10A and shLuc MCF-10A by western blot analysis. The
upper band is phospho-Smad2 and the asterisk indicates the lower non-specific band. (B)
The mRNA level of Smad7 was measured in TGF-β1-treated and untreated SAP30
depleted MCF-10A and shLuc MCF-10A by Real-Time PCR. The average of three
independent experiments is shown. The asterisks indicate a statistically significant
difference of treated samples from untreated samples (Student's t test; P < 0.05). The
error bars indicate one standard deviation from the mean. All values for Real-Time PCR
experiments were normalized to the level of GAPDH mRNA abundance.
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3.1.5.3

E2F target genes are repressed by TGF-β in absence of
SAP30

In many cell types, TGFβ activates the transcription of CDK inhibitors such as
p15 and p21 and downregulates the expression of proliferative genes including Cdc25A,
c-Myc. The net result of these transcriptional changes is CDK activity inhibition, which
results in dephosphorylation of pRB and repression of E2F target genes necessary for the
G1/S phase transition (221-226). To determine the status of E2F target genes expression
in SAP30 depleted cells in response to TGF-β, Real-Time PCR was performed to
measure the mRNA level of three E2F-responsive genes in response to TGF-β. As shown
in Figure 3-6, levels of PCNA, CCNE1 and CCNA2 transcripts decreased in both SAP30
depleted and shLuc MCF-10A cells in response to TGF-β. Our previous experiments
using Rb1ΔL MEFs showed that pRb`s ability to repress transcription of E2F responsive
genes in response to TGF-β1 is lost. This suggests that pRB also needs LxCxE binding
partner to repress transcription of E2F target genes. As this result shows, depletion of
SAP30 compromises TGF-β growth arrest; however, SAP30 serves this role in an E2F
independent manner, because E2F target genes are repressed in absence of SAP30 in
response to TGF-β. Therefore, SAP30 is not our desired component.
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Figure 3-6 E2F target genes are repressed in response to TGF-βinabsenceof
SAP30
(A-C) The mRNA level of CCNE1, CCNA2 and PCNA was measured in TGF-β1 treated
and untreated SAP30 depleted MCF-10A and shLuc MCF-10A by Real-Time PCR. All
values for Real-Time PCR experiments were normalized to the level of GAPDH mRNA
abundance. The average of three independent experiments is shown. The asterisks
indicate a statistically significant difference of treated samples from untreated samples
(Student's t test; P < 0.05). The error bars indicate one standard deviation from the mean.
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3.1.6

MTA2, a unique component of NuRD complex involved in
E2F transcriptional repression
MTA2 is essential in the assembly of an active histone HDAC complex and the

association of MTA2 with the core HDAC complex requires MBD3 (276). It has also
been shown that one of the mechanisms by which E2F-pRB mediates repression of E2F
target genes is through recruitment of HDAC (51); Therefore, MTA2 may have a role in
E2F transcriptional repression in response to TGF-β1. This motivated us to examine the
effect of MTA2 in TGF-β1 mediated growth arrest.

3.1.6.1

Depletion of MTA2 compromises TGF-β growth arrest

To examine whether MTA2 is involved in TGF-β1-induced growth arrest, 3×105
MCF-10A cells were plated in 6 cm plates in duplicate. Then, these cells were infected
with lentiviral vector carrying MTA2 shRNA along with shLuc as a control. After
lentiviral infection and selection with puromycin, the infected cells were expanded for
further experiments.
To confirm knockdown efficiency, 4×105 infected MCF-10A cells were plated in
6 cm plates in duplicate for MTA2 shRNA and shLuc. TGF-β1 (100 pM) was added to
one plate of each shRNA for 24 hours. After TGF-β1 treatment, RNA was isolated and
converted to cDNA and Real-Time PCR was performed for MTA2. As shown in Figure
3-7A, the level of MTA2 transcript was significantly reduced in MCF-10A cells.
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To do TGF-β1 growth arrest assay, 4×105 infected MCF-10A cells were plated in
6 cm plates in duplicate for each shRNA. TGF-β1 (100 pM) was added to one plate of
each shRNA. After 24 hours TGF-β1 treatment, the cells were pulse-labeled with BrdU
for 4 hours. Then, flow cytometry was performed to quantify the number of cells
incorporating BrdU. As shown in Figure 3-7B, MCF-10A cells expressing shLuc showed
a significant decrease in BrdU incorporation in response to TGF-β1 whereas the ability of
MTA2 depleted cells to induce to TGF-β1 growth arrest was reduced. This suggests that
depletion of MTA2 compromises TGF-β1-induced growth arrest.
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Figure 3-7 Depletion of MTA2 compromises TGF-β1 mediated growth arrest
(A) MCF-10A cells were infected with shRNA to deplete the expression of MTA2.
After infection and three days selection, the infected cells were treated with TGF-β1 for
24 hours; the mRNA level of MTA2 was measured by Real-Time PCR to verify
knockdown efficiency. All values for Real-Time PCR experiments were normalized to
the level of GAPDH mRNA abundance. (B) MTA2 depleted cells were treated with
TGF-β1 for 24 hours, pulse-labeled with BrdU for 4 hours. The percentage of cells
incorporating BrdU was measured by flow cytometry. The average of three independent
experiments is shown. The asterisks indicate a statistically significant difference from
untreated shLuc (Student's t test; P < 0.05). The error bars indicate one standard deviation
from the mean. (+ve, positive)
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3.1.6.2

TGF-β signaling is intact in absence of MTA2

In order to investigate whether depletion of MTA2 affects TGF-β1 signaling
pathway upstream of pRB dephosphorylation and activation, the ability of MTA2
depleted MCF-10A cells to phosphorylate Smad2 in response to TGF-β1 was examined.
To do this, 2.8×107 MTA2 depleted MCF-10A cells were plated in 15 cm plates in
duplicate along with MCF-10A cells infected by shLuc as a control and treated one plate
of each with TGF-β1 (100 pM) for 24 hours. After treatment with TGF-β1, the nuclear
extract was isolated and was blotted for phospho-Smad2. As shown in Figure 3-8A,
Smad2 is phosphorylated in response to TGF-β1 in absence of MTA2. This suggests that
depletion of MTA2 does not block TGF-β1 receptor expression and function. In addition,
the Smad-dependent transcription of MTA2 depleted MCF-10A cells was examined; To
do this, Real-Time PCR was performed to look at the transcription level of Smad7. As
shown in Figure 3-8B, Smad complexes are able to activate transcription of Smad7 in the
absence of MTA2 suggesting that Smad-dependent transcription is intact in absence of
MTA2.
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Figure 3-8 TGF-βsignalingisintactinabsenceofMTA2
(A) Total phospho-Smad2 expression levels were measured in TGF-β1-treated and
untreated MTA2 depleted MCF-10A and shLuc MCF-10A by Western blot analysis. (B)
The mRNA level of Smad7 was measured in TGF-β1-treated and untreated MTA2
depleted MCF-10A and shLuc MCF-10A by Real-Time PCR. All values for Real-Time
PCR experiments were normalized to the level of GAPDH mRNA abundance. The
average of three independent experiments is shown. The asterisks indicate a statistically
significant difference from treated samples (Student's t test; P < 0.05). The error bars
indicate one standard deviation from the mean.
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3.1.6.3

E2F target genes are deregulated in response to TGF-β in
absence of MTA2

To determine the status of E2F target genes expression in the absence of MTA2
and in response to TGF, Real-Time PCR was performed to measure the mRNA level of
three E2F-responsive genes including PCNA, CCNE1 and CCNA2 in response to TGF-β.
As shown in Figure 3-9, these E2F target are repressed in response to TGF-β1 in shLuc
MCF-10A cells. However, MTA2 depleted MCF-10A cells show a slight increase in the
expression of E2F target genes. This suggests that E2F target genes are derepressed in
MTA2 depleted cells. This finding is consistent with previous experiment in our lab
suggesting that E2F target genes are derepressed in Rb1ΔL MEFs in response to TGF-β1.
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Figure 3-9 E2F target genes are deregulated in response to TGF-βinabsence
of MTA2
(A-C) The mRNA level of CCNA2, CCNE1 and PCNA was measured in TGF-β1-treated
and untreated MTA2 depleted MCF-10A and shLuc MCF-10A by Real-Time PCR. The
average of three independent experiments is shown. The asterisks indicate a statistically
significant difference from untreated shLuc (Student's t test; P < 0.05). The error bars
indicate one standard deviation from the mean. All values for Real-Time PCR
experiments were normalized to the level of GAPDH mRNA abundance.
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4

Discussion
4.1 Summary
pRB is a key regulator of cell proliferation in the G1 phase of the cell cycle.

Previously, it was thought that pRB`s function as a tumor suppressor was only due to its
ability to inhibit E2F target gene transcription in the G1 phase. Now, it is believed that
there are many proteins, which cooperate with pRB to act as a tumor suppressor. TGF-β
induces G1 growth arrest by inhibiting CDK`s activity which leads to dephosphorylation
and activation of pRB (63, 64). While many scientists did not consider TGF-β as a part of
the pRB pathway; our lab, using a knock-in mouse that carries a three amino acid
substitution mutant to disrupt LxCxE cleft in pRB (called Rb1∆L), showed that mammary
epithelial cells from Rb1ΔL/ΔL mice do not respond to TGF-β-induced growth arrest (261).
We found that TGF-β stimulation of epithelial cells results in dephosphorylation of pRB
and the defect in growth inhibition is downstream of pRB’s activation. Furthermore,
repression of E2F responsive cell cycle genes is defective in the Rb1ΔL/ΔL cells in response
to TGF-β (261). This shows that the interactions mediated by the LxCxE binding cleft of
pRB are necessary for TGF-β mediated growth arrest. Using shRNAs to deplete the
expression of chromatin regulating complexes, we tried to identify specific proteins,
which interact with pRB through the LxCxE binding cleft in mediating E2F target gene
repression in response to TGF-β. First, data showed that TGF-β mediated growth arrest is
pRB dependent in MCF-10A cells and pRB depletion deregulates E2F target gene
expression in these cells confirming that these cells are a suitable system for our study.
Then, our results showed that the depletion of MTA2 and SAP30 compromises TGF-β
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mediated growth arrest. In addition, depletion of MTA2 and SAP30 did not block TGFβ1 signaling upstream of pRB as demonstrated by phosphorylation of Smad2 and
upregulation of Smad7 level. Furthermore, depletion of MTA2 resulted in derepression of
E2F target genes in response to TGF-β while depletion of SAP30 repressed the
expression of E2F target genes. These data suggest that SAP30 induces TGF-β1 mediated
arrest in an E2F independent manner. It has been demonstrated that TGF-β enhances the
interaction of pRB with the MCM complex at the G1 phase of the cell cycle, which
prevents the activation of replication origin and the G1- S phase transition (277).
Although we currently do not know how pRB controls MCM function molecularly. One
possible explanation is that pRB recruits other regulatory factors to MCM complexes to
mediate this interaction. Since our data suggests that SAP30 mediates TGF-β growth
arrest independent of E2F transcription, it is possible that SAP30 plays a role in pRB`s
interaction with replication origins to induce growth inhibition. In addition, our data
suggests that MTA2 is involved in an E2F dependent TGF-β1 mediated growth arrest. In
summary, SAP30 and MTA2 are involved in TGF-β1 mediated growth arrest. However,
they will use different mechanisms to induce growth inhibition.

4.2 Plausible mechanisms of MTA2 mediated TGF-β
growth arrest
These findings suggest that MTA2 is one of the components involved in E2F
transcriptional repression in response to TGF-β. There are several possibilities for how
MTA2 represses the transcription of E2F target genes and how this protein induces TGFβ mediated growth arrest (Figure 4-1).
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One possibility is that MTA2 in the NuRD complex is recruited independent of
LxCxE interaction and through the direct interaction with chromatin, because the Cterminal domain of MTA proteins in the NuRD complex directly interacts with histone
H3 tails (278). Furthermore, it has been shown that the NuRD complex can be recruited
to chromatin through the interaction with other proteins (278). One example is that the
NuRD complex can associate with chromatin by interacting with different co-factors such
as HP1. In this case, NuRD complex is recruited to E2F target genes through the direct
interaction of MTA2 with chromatin. Once recruited, the NuRD complex uses its ability
to remodel chromatin structure and repress the transcription of E2F target genes (Figure
4-1A).
Another possibility is that MTA2 in the NuRD complex is recruited through
HDAC1, because HDAC1 can bind to pRB through the LxCxE binding cleft and MTA2
is required for the assembly of HDAC complex (51, 276). In this scenario, pRB recruits
the NuRD complex through the HDAC1 interaction to E2F target genes promoters. Once
recruited, the NuRD complex changes chromatin dynamics and represses E2F target
genes transcription (Figure 4-1B). Since MTA2 directs the assembly of the complex, its`
depletion makes the complex incapable of repressing E2F target genes transcription in
response to TGF-β. This will lead to defective TGF-β mediated growth arrest in absence
of MTA2.
Lastly, the NuRD complex may interact with chromatin through the MBD2
subunit, which has the ability to bind to the methylated DNA (279). In this scenario, pRB
interacts with DNMT1, an enzyme responsible for catalyzing DNA methylation of
promoters, through the LxCxE binding cleft (280, 57). Once E2F target genes are
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methylated, MBD2 subunit in the NuRD complex binds to the methylated DNA and
recruits the NuRD complex to E2F target genes. The NuRD complex has the HDAC
activity and once it is recruited, can repress transcription of E2F target genes by
deacetylating histones on E2F target genes` promoter (Figure 4-1C). The experiments
proposed in the next section will examine these models.
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Figure 4-1 Plausible mechanisms of MTA2 mediated TGF-β growth arrest
(A) NuRD complex is recruited to E2F target genes through the direct interaction of
MTA2 with chromatin. Once recruited, the NuRD complex uses its ability to remodel
chromatin structure and repress the transcription of E2F target genes. (B) pRB recruits
the NuRD complex through HDAC1 interaction with E2F target genes promoters. Once
recruited, the NuRD complex changes chromatin dynamics and represses E2F target
genes transcription. (C) pRB interacts with DNMT1 through the LxCxE binding cleft.
Once E2F target genes are methylated, MBD2 subunit in the NuRD complex binds to the
methylated DNA and recruits the NuRD complex to E2F target genes. The NuRD
complex has the HDAC activity and once it is recruited, can repress transcription of E2F
target genes by deacetylating histones on E2F target genes promoter.
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4.3 Further investigating of the mechanism of MTA2
mediated TGF-β growth arrest
To examine our proposed models, we can use shRNAs against DNMT1 and
MBD2 to knockdown their expression and examine whether depletion of these proteins
compromise TGF-β mediated growth arrest. In addition, we can use methylation specific
PCR for E2F target genes after TGF-β treatment to investigate if they become methylated
in response to TGF-β and if their methylation pattern will change after DNMT1 and
MBD2 knockdown. If DNA methylation is a mechanism by which the NuRD complex
serves to induce the growth arrest, we expect that depletion of DNMT1 and MBD2
compromise the growth arrest. Furthermore, since the NuRD complex has the HDAC
activity and MTA2 can direct the assembly of an active HDAC complex, it is logical to
examine the acetylation changes at E2F target genes in the absence of MTA2 in response
to TGF-β1. To this end, MTA2-depleted MCF-10A would be treated with TGF-β1. Then
chromatin immunoprecipitation (ChIP) assays will be performed to look at histone tail
modifications using pan acetyl-Histone H3 antibody and pan acetyl-Histone H4 antibody.
To do this, DNA released from precipitated complexes will be amplified by PCR using
primers specific to the promoter regions of E2F target genes such as PCNA, CCNE1,
CCNA2. The same ChIP assays also can be performed to determine whether MTA2 is
recruited to E2F target genes promoter in a TGF-β1 dependent manner.
Additionally, immunoprecipitation (IP) assays for other components of NuRD
complex in absence of MTA2 can be performed to ensure that the complex integrity is
intact in absence of MTA2 and the complex does not fall apart upon depletion of MTA2.
This experiment would tell us whether MTA2 has a very specific role in TGF-β induced
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arrest and its loss leaves the rest of the complex alone or the NuRD complex is
completely disrupted by MTA2 depletion and that would explain why this would disrupts
its ability to arrest proliferation.
In summary, these experiments identify how the NuRD complex cooperates with
pRB in response to TGF-β1 and determine how these downstream targets of the pRBLxCxE interaction function in response to TGF-β1 in this critical cancer-suppressing
pathway.

4.4 Other potential LxCxE partners involved in TGF-β
growth arrest
In addition to MTA2 and SAP30, there are other components in both Sin3 and
NuRD complexes, which associate with HDAC. Therefore, they may have a role in
transcriptional repression of E2F target genes in response to TGF-β. One such example is
SDS3. SDS3 mutants showed very similar phenotypes previously observed in Sin3,
suggesting that SDS3 plays an essential role in the Sin3 complex (281). Depletion of
SDS3 results in a dramatic loss of HDAC activity and a significant reduction in Sin3mediated repression (119). SDS3-deﬁcient cells fail to deacetylate pericentric
heterochromatin histones, resulting in a general failure of cytokinesis and aneuploidy.
These studies indicate that SDS3 is a core subunit in the Sin3 complex and augments
HDAC activity. Therefore, it may have a role in transcriptional repression of E2F target
genes in response to TGF-β.
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In addition to Sin3 and NuRD complexes, CtBP binds to pRB through the LxCxE
binding cleft. It appeared that CtBP mediates transcriptional repression in a HDACdependent or HDAC-independent manner (135, 282). It has been suggested that CtBP
mediates HDAC-independent repression through the recruitment of the Polycomb-group
(PcG) complex and pRB by CtIP (283). Since CtBP serves its role as a transcriptional
repressor through the recruitment of HDAC as well as PcG, it may have a role in
transcriptional repression of E2F target genes in response to TGF-β.
The complexes mentioned above (Sin3, NuRD and CtBP) contain subunits which
are able to modify chromatin structure resulting in the loss of pRB proliferative control.
For example, LSD1 is a component of the NuRD, which is capable of demethylating
H3K4me2 from nucleosomes (284). Furthermore, it has been demonstrated that
trimethylation of histone 3 lysine 9 (H3K9Me3), which is mediated by Suv39h1 enzyme,
is reduced at the E2F target genes at the senescent Rb1∆L cells (100) and also long term
exposure to TGF-β1 can induce cellular senescence (285). To complement shRNA
approach and identify the other potential LxCxE partners, we can further investigate the
chromatin modifications at E2F target genes after TGF-β1 treatment. To this end, Rb1∆L
MECs will be treated with TGF-β1. Then, ChIP assays will be performed to look at
histone tail modifications using methyl/acetyl-Histone H3 antibody and methyl/acetylHistone H4 antibody. DNA released from precipitated complexes will be amplified by
PCR using primers specific to the promoter regions of E2F target genes such as Pcna,
Ccne1, Mcm3 and Mcm5.
As a result, these experiments will determine chromatin structure changes at E2F
target genes promoters in response to TGF-β1. This way, the change in chromatin
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structure after TGF-β1 treatment will lead us to pick suitable components to continue
forward in the experiments. These experiments will also determine the requirement of
LxCxE interacting proteins in TGF-β1 mediated growth arrest.

4.5 An unbiased approach to identify LxCxE partners
involved in TGF-β growth arrest
Many potential candidates have been identified that may cooperate with pRB in
an LxCxE dependent manner to induce TGF-β mediated growth arrest. With such a
diverse list, alternative approaches may be required to determine the mechanism behind
of pRB-LxCxE dependent TGF-β mediated growth arrest. One unbiased approach would
utilize shRNA library screening to identify proteins cooperating with pRB in response to
TGF-β1 by knocking down proteins at random. To do this, NMuMG-Fucci cell line, a
subline of the NMuMG cell line expressing a cell cycle marker, will be used. Fucci
technology allows dual-color imaging, which can distinguish between live cells in the
G1 (red) and the S/G2/M phases (green) (286). After knocking down with shRNA
library, the cells would be tested for TGF-β1-induced growth arrest and those proteins,
which cooperate with pRB in TGF-β1-induced growth arrest, can be identified. As a
result, these experiments will identify the identity of any remaining LxCxE interacting
proteins in TGF-β1 mediated growth arrest.
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4.6 Therapeutic potential of uncovering the exact
mechanism of TGF-β mediated growth arrest
TGF-β has a tumor promoting effect in tumor development, when carcinoma cells
become insensitive to TGF-β induced growth inhibition (142). Furthermore, the majority
of triple-negative breast cancers (TNBCs) recur after chemotherapy. A subpopulation of
cancer stem cells (CSCs) drives recurrences following treatment with anticancer
chemotherapy (287, 288). Chemotherapy induces TGF-β activity, which has been shown
to induce these tumor stem-like properties (289). Thus, TGF inhibitors are being
developed by pharmaceuticals as anti-metastatic therapies in patients with this cancer to
decrease the CSC population to prevent TNBC recurrences. However, TGF-β is essential
for normal development and plays crucial roles in wound healing, inflammation and
tissue repair; therefore, using these TGF-β inhibitors may create life-threatening side
effects in other tissues later in life.
Since TGF-β has a dual role in tumorigenesis, the detailed understanding of TGFβ signaling pathways is required in order to differentiate between tumor suppressor and
promoting effect of TGF-β to prevent unwanted side effects in other tissues. In order to
develop new therapeutics that targets the TGF-β signaling pathway in tumor progression,
it is important to determine the unique components that mediate the tumor promoting or
tumor suppressor properties of TGF-β. My project provides an excellent opportunity to
elucidate the exact growth-controlling mechanism and determine the unique components
of tumor suppressor properties of TGF-β. My project provides a better understanding of
the TGF-β growth inhibitory pathway in order to distinguish it from tumor promoting
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role of TGF-β. This will lead to find better therapy for breast cancer patients, which
minimizes unwanted off-target side effects in these patients.
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